<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1491249</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2024.1491249</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Nitazoxanide mitigates methotrexate hepatotoxicity in rats: role in inhibiting apoptosis and regulating endoplasmic reticulum stress</article-title>
<alt-title alt-title-type="left-running-head">Mahmoud et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1491249">10.3389/fphar.2024.1491249</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mahmoud</surname>
<given-names>Nevertyty Mohamed</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2835968/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Elshazly</surname>
<given-names>Shimaa M.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2825210/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>El-shaarawy</surname>
<given-names>Fatma</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zaitone</surname>
<given-names>Sawsan A.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aldahish</surname>
<given-names>Afaf A.</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1529239/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ahmed</surname>
<given-names>Gehan A.</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fawzy</surname>
<given-names>Manal S.</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
<xref ref-type="aff" rid="aff9">
<sup>9</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/644381/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aloyouni</surname>
<given-names>Sheka Yagub</given-names>
</name>
<xref ref-type="aff" rid="aff10">
<sup>10</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1149265/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abed</surname>
<given-names>Sally Y.</given-names>
</name>
<xref ref-type="aff" rid="aff11">
<sup>11</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2175578/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Saeedi</surname>
<given-names>Tahani</given-names>
</name>
<xref ref-type="aff" rid="aff12">
<sup>12</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>El-Sayed</surname>
<given-names>Shaimaa S.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Clinical Pharmacology</institution>, <institution>Faculty of Medicine</institution>, <institution>Zagazig University</institution>, <addr-line>Zagazig</addr-line>, <country>Egypt</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Pharmacology and Toxicology</institution>, <institution>Faculty of Pharmacy</institution>, <institution>Zagazig University</institution>, <addr-line>Zagazig</addr-line>, <country>Egypt</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Biochemistry</institution>, <institution>Faculty of Pharmacy</institution>, <institution>Sinai University</institution>, <addr-line>Arish</addr-line>, <country>Egypt</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Pharmacology and Toxicology</institution>, <institution>Faculty of Pharmacy</institution>, <institution>Suez Canal University</institution>, <addr-line>Ismailia</addr-line>, <country>Egypt</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Pharmacology and Toxicology</institution>, <institution>Faculty of Pharmacy</institution>, <institution>University of Tabuk</institution>, <addr-line>Tabuk</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Department of Pharmacology</institution>, <institution>College of Pharmacy</institution>, <institution>King Khalid University</institution>, <addr-line>Abha</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff7">
<sup>7</sup>
<institution>Forensic Medicine and Clinical Toxicology Department</institution>, <institution>Faculty of Medicine</institution>, <institution>Zagazig University</institution>, <addr-line>Zagazig</addr-line>, <country>Egypt</country>
</aff>
<aff id="aff8">
<sup>8</sup>
<institution>Department of Biochemistry</institution>, <institution>Faculty of Medicine</institution>, <institution>Northern Border University</institution>, <addr-line>Arar</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff9">
<sup>9</sup>
<institution>Center for Health Research</institution>, <institution>Northern Border University</institution>, <addr-line>Arar</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff10">
<sup>10</sup>
<institution>Research Department</institution>, <institution>Natural and Health Sciences Research Center</institution>, <institution>Princess Nourah bint Abdulrahman University</institution>, <addr-line>Riyadh</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff11">
<sup>11</sup>
<institution>Department of Respiratory Care</institution>, <institution>College of Applied Medical Science in Jubail</institution>, <institution>Imam Abdulrahman Bin Faisal University</institution>, <addr-line>Jubail</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff12">
<sup>12</sup>
<institution>Department of Pharmacology and Toxicology</institution>, <institution>School of Pharmacy</institution>, <institution>Taibah University</institution>, <addr-line>Medina</addr-line>, <country>Saudi Arabia</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/360588/overview">Anna Maria Giudetti</ext-link>, University of Salento, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/115276/overview">Daniele Vergara</ext-link>, University of Salento, Italy</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2848956/overview">Azza Awad</ext-link>, Al-Azhar University, Egypt</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Shimaa M. Elshazly, <email>smelshazly@pharmacy.zu.edu.eg</email>; Sawsan A. Zaitone, <email>sawsan_zaytoon@pharm.suez.edu.eg</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="ecorrected">
<day>01</day>
<month>09</month>
<year>2026</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1491249</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>09</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>11</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Mahmoud, Elshazly, El-shaarawy, Zaitone, Aldahish, Ahmed, Fawzy, Aloyouni, Abed, Saeedi and El-Sayed.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Mahmoud, Elshazly, El-shaarawy, Zaitone, Aldahish, Ahmed, Fawzy, Aloyouni, Abed, Saeedi and El-Sayed</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Objectives</title>
<p>Hepatotoxicity is a severe outcome of methotrexate (MTX) therapy, limiting its clinical use and contributing to its related morbidity and mortality. This study investigated the hepatoprotective effects of nitazoxanide (NTZ), an antiprotozoal drug, against MTX-induced hepatotoxicity and whether endoplasmic reticulum (ER) stress-modulation underlies the expected beneficial effects of NTZ.</p>
</sec>
<sec>
<title>Methods</title>
<p>Thirty-six rats were allocated to six groups, one control group and five MTX groups, where induction of hepatotoxicity was achieved via injecting MTX (20&#xa0;mg/kg). Groups were assigned as MTX-vehicle, NTZ-100, and NTZ-200 groups (at 100 and 200&#xa0;mg/kg/day, gavage, respectively), N-acetyl cysteine (NAC) group (500&#xa0;mg/kg), and 4-phenyl butyric acid (4-PBA) group (150&#xa0;mg/kg, i.p). Liver function enzymes in serum, hepatic oxidative stress, proinflammatory cytokines, apoptosis, and ER-stress biomarkers were assessed. A histopathological examination was performed.</p>
</sec>
<sec>
<title>Results</title>
<p>Treatment with NTZ lessened the serum liver enzymes, reduced malondialdehyde (lipid peroxidation product), enhanced antioxidant capacity, attenuated proinflammatory cytokines, and suppressed apoptosis. The protective effect of NTZ was dose-dependent, and the findings observed with the high-dose NTZ were similar to those obtained with the ER-stress inhibitor (4-PBA).</p>
</sec>
<sec>
<title>Conclusion</title>
<p>NTZ exerted a hepatoprotective effect in MTX-challenged rats that is mediated via modulation of ER stress and inhibiting apoptosis.</p>
</sec>
</abstract>
<abstract abstract-type="graphical">
<title>Graphical Abstract</title>
<p>
<graphic xlink:href="fphar-15-1491249-abs.tif"/>
</p>
</abstract>
<kwd-group>
<kwd>nitazoxanide</kwd>
<kwd>methotrexate</kwd>
<kwd>hepatotoxicity</kwd>
<kwd>endoplasmic reticulum stress</kwd>
<kwd>rat</kwd>
</kwd-group>
<contract-num rid="cn001">PNURSP 2024R713</contract-num>
<contract-sponsor id="cn001">Princess Nourah Bint Abdulrahman University<named-content content-type="fundref-id">10.13039/501100004242</named-content>
</contract-sponsor>
<counts>
<page-count count="18"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Gastrointestinal and Hepatic Pharmacology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Methotrexate (MTX) is a dihydrofolate reductase inhibitor and chemotherapeutic agent with proven efficiency against cancers and rheumatoid arthritis (<xref ref-type="bibr" rid="B48">Kozminski et al., 2020</xref>). Despite the high efficacy-to-toxicity ratio, MTX toxicity remains a significant concern that leads to a limitation on its use (<xref ref-type="bibr" rid="B81">Shea et al., 2013</xref>). Adverse outcomes among patients on MTX include hepatotoxicity, hematotoxicity, testiculopathy, and lung problems (<xref ref-type="bibr" rid="B81">Shea et al., 2013</xref>). MTX-induced liver toxicity is characterized by increased levels of aminotransferases, the development of hepatic steatosis, and progression to liver fibrosis and cirrhosis. This condition may be linked to the depletion of folate reserves in the liver due to MTX treatment (<xref ref-type="bibr" rid="B17">Conway and Carey, 2017</xref>).</p>
<p>Oxidative stress, which results from the excess production of &#x201c;reactive oxygen species (ROS),&#x201d; has a fundamental role in the MTX-associated toxicities pathogenesis (<xref ref-type="bibr" rid="B33">Herman et al., 2005</xref>; <xref ref-type="bibr" rid="B3">Abbas et al., 2023b</xref>) and is related to its cytotoxic effects (<xref ref-type="bibr" rid="B89">Tunali-Akbay et al., 2010</xref>; <xref ref-type="bibr" rid="B12">&#xc7;a&#x11f;lar et al., 2013</xref>). Accumulated ROS upon MTX therapy attenuates antioxidant capacity in the liver and further attacks membrane lipids via lipid peroxidation, disrupting membrane integrity and eventually leading to tissue damage (<xref ref-type="bibr" rid="B6">Al Maruf et al., 2018</xref>; <xref ref-type="bibr" rid="B39">Jahovic et al., 2003</xref>; <xref ref-type="bibr" rid="B5">Ali et al., 2017</xref>).</p>
<p>The endoplasmic reticulum (ER) is a fundamental cellular organelle responsible for the newly synthesized proteins folding into their final 3-dimentional structures, post-translational modification, transportation, and quality control (<xref ref-type="bibr" rid="B74">Perri et al., 2016</xref>). In various pathological conditions implicating oxidative stress, ER functions are disturbed resulting in ER stress and initiation and propagation of unfolded protein response (UPR), which results in transient suppression of protein translation to allow recovery but leads to cell death when stress cannot be resolved (<xref ref-type="bibr" rid="B83">Soliman et al., 2019</xref>). Redox-controlled reversible modifications regulate UPR signaling, for example, thiol oxidation of ER molecular chaperones such as the binding immunoglobulin protein/78-kDa glucose-regulated protein (BiP/Grp78) that enhances the release of BiP from ER stress sensors and activates UPR (<xref ref-type="bibr" rid="B93">Wang et al., 2014</xref>). Another example is cysteine sulfhydration of protein tyrosine phosphatase 1B (PTP1B) that promotes phosphorylation and activation of double-stranded RNA-activated protein kinase-like ER kinase (PERK), a key ER stress sensors (<xref ref-type="bibr" rid="B50">Krishnan et al., 2011</xref>). In addition, ROS mediate cysteine sulfenylation of another ER stress sensor, inositol requiring enzyme 1&#x3b1; (IRE1&#x3b1;), which activates nuclear factor-E2-related factor-2 (Nrf2) to generate an antioxidative response (<xref ref-type="bibr" rid="B36">Hourihan et al., 2016</xref>). Further, one chaperone upregulated during the UPR is Protein Disulfide Isomerase (PDI), which is an essential redox-sensitive activator of PERK (<xref ref-type="bibr" rid="B49">Kranz et al., 2017</xref>). Despite that UPR helps cells to cope with ER stress, prolonged ER stress induces apoptotic cell death where the accumulation of unfolded protein in ER results in increased expression activating transcription factor 4 (ATF-4) that in turn increases the transcription of the proapoptotic protein, C/EPB&#x3b1;-homologous protein-10 (CHOP-10) (<xref ref-type="bibr" rid="B58">Li et al., 2014</xref>).</p>
<p>Apoptosis is essential in cellular homeostasis maintenance and is activated during adverse conditions (<xref ref-type="bibr" rid="B23">Elmore, 2007</xref>). Antitumor effects of MTX are, in part, attributed to apoptosis induction in many cancers (<xref ref-type="bibr" rid="B73">Pawlak et al., 2017</xref>; <xref ref-type="bibr" rid="B94">Wei et al., 2019</xref>). Unfortunately, MTX can trigger apoptosis in healthy tissues, including the liver (<xref ref-type="bibr" rid="B3">Abbas et al., 2023b</xref>). ROS signaling is crucial in mediating apoptosis induced by MTX, further deteriorating MTX-induced cytotoxicity (<xref ref-type="bibr" rid="B95">Xiong et al., 2020</xref>). Research has revealed that ER stress is associated with nephrotoxicity induced by MTX as well as hepatic stellate cells (HSCs) activation (<xref ref-type="bibr" rid="B46">Koo et al., 2016</xref>; <xref ref-type="bibr" rid="B84">Song et al., 2021</xref>). MTX-induced ER stress occurs predominantly through the PERK/CHOP-10 pathway (<xref ref-type="bibr" rid="B46">Koo et al., 2016</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>The endoplasmic reticulum (ER) serves as a cellular compartment where proteins undergo folding with lumenal chaperones. When misfolded proteins build up within the ER, this induces ER stress and triggers a signaling cascade known as the &#x201c;unfolded protein response (UPR).&#x201d; The &#x201c;PERK/CHOP-10 pathway&#x201d; is indicated by purple arrows. Nonetheless, in extreme conditions, the UPR&#x2019;s protective measures are inadequate to reestablish proper ER function, leading to cellular apoptosis. &#x201c;PERK, Protein Kinase R-like ER Kinase; eIF2&#x3b1;, eukaryotic translation initiation factor 2 subunit alpha; ATF4/6, activating transcription factor 4/6; S1/2P, membrane-bound transcription factor site-1/2 protease; CHOP, DNA damage-inducible transcript 3; IRE1, endoplasmic reticulum to nucleus signaling 1; TRAF2, TNF receptor-associated factor 2; ASK1, Apoptosis signal-regulating kinase 1; MKK7, mitogen-activated protein kinase kinase 7; XBP, X-box binding protein 1.&#x201d; Adopted from (<ext-link ext-link-type="uri" xlink:href="https://www.genome.jp/pathway/hsa04141+N01009">https://www.genome.jp/pathway/hsa04141&#x2b;N01009</ext-link>) (last acceded 26 July 2024) (<xref ref-type="bibr" rid="B42">Kanehisa et al., 2016</xref>).</p>
</caption>
<graphic xlink:href="fphar-15-1491249-g001.tif"/>
</fig>
<p>Nitazoxanide (NTZ) is commonly used to treat diarrhea caused by Giardia intestinalis (<xref ref-type="bibr" rid="B1">Abaza et al., 1998</xref>). It exhibits anti-infective, anti-inflammatory, and antineoplastic activities (<xref ref-type="bibr" rid="B78">Rossignol, 2014</xref>; <xref ref-type="bibr" rid="B18">Di Santo and Ehrisman, 2013</xref>; <xref ref-type="bibr" rid="B80">Shakya et al., 2018</xref>; <xref ref-type="bibr" rid="B4">Abd El-Fadeal et al., 2021</xref>). NTZ effectively reduces oxidative stress induced by the influenza-A virus (<xref ref-type="bibr" rid="B37">Huang et al., 2023</xref>) and mitigates proinflammatory cytokine release in macrophages triggered by lipopolysaccharide (<xref ref-type="bibr" rid="B35">Hong et al., 2012</xref>). Recently, NTZ has been repurposed to treat hyperlipidemia, hepatic steatosis (<xref ref-type="bibr" rid="B55">Li et al., 2022</xref>), as well as atherosclerosis (<xref ref-type="bibr" rid="B61">Ma et al., 2023</xref>). NTZ acts as a noncompetitive inhibitor of PDI; thus influencing PERK signaling (<xref ref-type="bibr" rid="B75">Piacentini et al., 2018</xref>).</p>
<p>The protective effects of NTZ against MTX-induced hepatotoxicity as well as the underlying mechanisms have not yet been explored previously. This study aims to investigate the hepatoprotective effects of NTZ utilizing a rat model of acute MTX-induced hepatotoxicity shedding some light on the mechanism of NTZ-mediated hepatoprotection with a focus on the possibility of modulation of oxidative stress, ER stress and apoptosis. The effects of NTZ were compared to those of the standard antioxidant, N-acetyl cysteine (NAC), as a well-documented hepatoprotective agent known to inhibit ER stress, and to those of 4-phenyl butyrate (4-PBA), a standard ER stress inhibitor (<xref ref-type="bibr" rid="B83">Soliman et al., 2019</xref>).</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>2 Materials and methods</title>
<sec id="s2-1">
<title>2.1 The experimental animals</title>
<p>Currently, we included 36 adult male albino Wistar rats (with a body mass range equal to 190&#x2013;230&#xa0;g, 8&#x2013;10&#xa0;weeks of age) supplied by the &#x201c;Faculty of Veterinary Medicine, Zagazig University.&#x201d; Rats were kept in hygienic laboratory conditions, including temperature (22&#xb0;C &#xb1; 3&#xb0;C), relative humidity (60% &#xb1; 10%), and normal light/dark cycle. Rats were given unrestricted access to water and a standard diet <italic>ad libitum</italic>. The research protocol got approval from the Zagazig University Animal Care and Use Committee (code number ZU-IACUC/3/F/228/2022).</p>
</sec>
<sec id="s2-2">
<title>2.2 Drugs and chemicals</title>
<p>We purchased MTX (MYLAN) from Haupt Pharma GmbH, Germany), NTZ was purchased from Medizen Pharmaceutical Ind (Alexandria, Egypt), N-acetylcysteine (NAC) was obtained from SEDICO (Giza, Egypt), whereas Sigma&#x2013;Aldrich company (MO, United States) provided Kolliphor<sup>&#xae;</sup> EL and 4-Phenylbutyric acid (4-PBA). Microemulsions of 4-PBA were freshly prepared in a 1:1:9 solution of (Kolliphor<sup>&#xae;</sup> EL (surfactant), ethanol, and saline). NTZ and NAC were dissolved in distilled H<sub>2</sub>O.</p>
</sec>
<sec id="s2-3">
<title>2.3 Experimental protocol and induction of hepatotoxicity</title>
<p>After an adaptation period of 2&#xa0;weeks. We induced hepatotoxicity in rats by one MTX injection (20&#xa0;mg/kg, i. p.) (<xref ref-type="bibr" rid="B40">Kalantar et al., 2019a</xref>) on day 7.</p>
<p>The animals were randomly divided into six experimental groups (six rats/group):<list list-type="simple">
<list-item>
<p>&#x2022; CTRL group (rats were injected intraperitoneally with saline on day 7 plus Kolliphor<sup>&#xae;</sup> EL from day 1- day 10),</p>
</list-item>
<list-item>
<p>&#x2022; MTX group (rats were injected MTX intraperitoneally on day 7 plus Kolliphor<sup>&#xae;</sup> EL throughout the experiment),</p>
</list-item>
<list-item>
<p>&#x2022; NTZ-100 and NTZ-200 groups (rats were injected intraperitoneally with MTX on day 7 plus NTZ (100 and 200&#xa0;mg/kg, daily) from day 1- day 10 by oral gavage, respectively, plus Kolliphor<sup>&#xae;</sup> EL from day 1- day 10) (<xref ref-type="bibr" rid="B21">Elaidy et al., 2018</xref>; <xref ref-type="bibr" rid="B55">Li et al., 2022</xref>).</p>
</list-item>
<list-item>
<p>&#x2022; NAC group (rats were injected intraperitoneally with MTX on day 7 plus NAC 500&#xa0;mg/kg/day throughout the experiment by oral gavage, plus Kolliphor<sup>&#xae;</sup> EL from day 1- day 10) (<xref ref-type="bibr" rid="B54">Li et al., 2018</xref>; <xref ref-type="bibr" rid="B83">Soliman et al., 2019</xref>).</p>
</list-item>
<list-item>
<p>&#x2022; 4-PBA group (rats were injected intraperitoneally with MTX on day 7 plus 4-PBA (150&#xa0;mg/kg) by intraperitoneal injection every other day (days 2, 4, 6, 8, and 10) (<xref ref-type="bibr" rid="B83">Soliman et al., 2019</xref>).</p>
</list-item>
</list>
</p>
<p>The administration of the drug began on the initial day of the experiment and was maintained for 10&#xa0;days.</p>
</sec>
<sec id="s2-4">
<title>2.4 Blood and tissue collection</title>
<p>Sodium pentobarbital (50 mg/kg, i. p) was used for inducing anesthesia in rats (<xref ref-type="bibr" rid="B64">Mohamed et al., 2020</xref>), and blood samples were obtained from the retro-orbital plexus. The collected blood was centrifuged at 2,000 &#xd7; g for 25&#xa0;min at 4&#xb0;C to separate serum samples, which were then stored at &#x2212;80&#xb0;C. Subsequently, the rats were euthanized by cervical dislocation. A laparotomy was performed to extract the liver, which was washed three times in saline solution and then dried. The liver was divided into portions: the first portion, from the largest hepatic lobule, was fixed in 10% formalin, while another portion, from a smaller lobule, was stored at &#x2212;80&#xb0;C. Later, liver homogenates were prepared in ice-cold phosphate-buffered saline and centrifuged at 2,000 &#xd7; g for 25&#xa0;min. The supernatants were then collected, aliquoted, and stored at &#x2212;80&#xb0;C.</p>
</sec>
<sec id="s2-5">
<title>2.5 Serum liver function parameters</title>
<p>For evaluating the liver function, serum levels of alanine transaminase (ALT)/aspartate transaminase (AST), and alkaline phosphatase (ALP) were measured using the Bio-Diagnostic colorimetric kits (Giza, Egypt).</p>
</sec>
<sec id="s2-6">
<title>2.6 Hepatic biomarkers assessment</title>
<sec id="s2-6-1">
<title>2.6.1 Oxidative stress biomarkers</title>
<p>Liver homogenates were utilized to assess hepatic malondialdehyde (MDA) and to evaluate the hepatic content of reduced glutathione (GSH) and superoxide dismutase (SOD) activity. Measurements were conducted using colorimetric kits (Bio-Diagnostic Co., Giza, Egypt).</p>
</sec>
<sec id="s2-6-2">
<title>2.6.2 Proinflammatory cytokines</title>
<p>To evaluate hepatic inflammatory status in the liver homogenates, levels of TNF-&#x3b1;, IL-1&#x3b2;, and IL-6 were measured. The TNF-&#x3b1; levels were determined using the rat TNF-&#x3b1; ELISA kit from Boster Biological Technology (CA, United States), while IL-1&#x3b2; and IL-6 levels were measured using the rat IL-1 beta/IL-1F2 Quantikine ELISA Kit and the rat IL-6 Quantikine ELISA Kit from R&#x26;D Systems (MN, United States), respectively.</p>
</sec>
<sec id="s2-6-3">
<title>2.6.3 Apoptotic biomarkers</title>
<p>Liver homogenates were used to quantify apoptosis markers. Bcl-2 and Bax levels were determined utilizing rat &#x201c;B-cell CLL/lymphoma 2 and apoptosis regulator BAX ELISA&#x201d; kits from CUSABIO (Wuhan, China). The Bax/Bcl-2 ratio was then calculated. Hepatic caspase-3 activity was measured utilizing a colorimetric assay kit purchased from Sigma Aldrich (MO, United States). Caspase-3 produces a colored end-product (p-nitroaniline, p-NA moiety). Detected P-NA is in direct proportion to caspase-3 concentration.</p>
</sec>
<sec id="s2-6-4">
<title>2.6.4 ER-stress markers</title>
<p>&#x201c;Inositol-requiring enzyme 1 (IRE1),&#x201d; a marker of ER stress, was identified in the tissue homogenate utilizing a rat ELISA kit (Shanghai YL Biotech, Shanghai, China). We used the &#x201c;quantitative reverse transcription-polymerase chain reaction (qRT-PCR)&#x201d; to measure the relative mRNA expressions of activating transcription factor-4 (ATF4), CHOP-10, Glucose-Regulated Protein 78 (GRP78), and PERK as markers for ER stress. Frozen hepatic samples were lysed using Qiazol reagent, and total RNA extraction was done with a QIAGEN RNAeasy Mini Kit (Hilden, Germany). For each sample, 10&#xa0;ng of total RNA was used to synthesize cDNA with Quantiscript reverse transcriptase from the QuantiTect Reverse Transcription Kit (QIAGEN, Hilden, Germany). The cDNA was amplified using a Syber Green I PCR-Master Kit from Fermentas (PA, United States). <xref ref-type="table" rid="T1">Table 1</xref> provides the sequences of the gene primers. The cycle threshold (CT) values of gene expression were normalized to the housekeeping gene &#x3b2;-actin, and the expression ratios were calculated using the &#x394;&#x394;CT method.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>The sequence of the primers used in the qRT-PCR experiment.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Target gene</th>
<th align="left">Primer sequence: 5&#x2032;&#x2013;3&#x2032;</th>
<th align="left">Accession number</th>
<th align="left">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">ATF4</td>
<td align="left">F: TCCTCGATACCAGCAAATCC<break/>R: ACCCATGAGGTTTGAAGTGC</td>
<td align="left">NM_024403.2</td>
<td align="left">
<xref ref-type="bibr" rid="B83">Soliman et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">CHOP10</td>
<td align="left">F: AGGTCCTGTCCTCAGATGAAA<break/>R: TAGGGATGCAGGGTCAAGAGT</td>
<td align="left">NM_024134.2</td>
<td align="left">
<xref ref-type="bibr" rid="B83">Soliman et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">GRP78</td>
<td align="left">F:5&#x2032;-GAC GCA CTT GGA ATG ACC CTT-3<break/>R: 5&#x2032;-TTGGTT TGC CCA CCT CCG AT-3&#x2032;</td>
<td align="left">NM_013083.2</td>
<td align="left">
<xref ref-type="bibr" rid="B57">Liu et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">PERK</td>
<td align="left">F: 5&#x2032;- GCCACAGAGAACAGCGTGTA-3&#x2032;<break/>R: 5&#x2032;-GATCGTCGGCAGAGGAATAA-3&#x2032;</td>
<td align="left">NM_031599.2</td>
<td align="left">
<xref ref-type="bibr" rid="B28">Chen et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="left">&#x3b2;-actin</td>
<td align="left">F: ATGGATGACGATATCGCTGC<break/>R: CTTCTGACCCATACCCACCA</td>
<td align="left">NM_031144.3</td>
<td align="left">
<xref ref-type="bibr" rid="B83">Soliman et al. (2019)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-6-5">
<title>2.6.5 Determination of the protein levels of endoplasmic reticulum stress markers by Western blotting and ELISA</title>
<p>Protein levels of phosphorylated PERK and CHOP-10 proteins were determined in the homogenate of the liver tissue. Proteins were denatured in Laemmli buffer. Subsequently, the protein samples in equal volume were run on a 13%&#x2013;15% sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, then moved to nitrocellulose membranes. The membrane was blocked in tris-buffered saline with Tween 20 (TBST) and 3% bovine serum albumin (BSA) at room temperature for 1&#xa0;h. The blots were probed with the primary antibodies specific for phosphorylated PERK and CHOP (Thermo Fischer Scientific Inc.) at 4&#xb0;C overnight, then the blots were rinsed 3&#x2013;5 times for 5&#xa0;min with TBST and incubated with the horseradish peroxidase (HRP)-conjugated anti-rabbit IgG Secondary Antibody (Thermo Fischer Scientific Inc.) against the blotted target protein for 1&#xa0;h at room temperature. The chemiluminescent substrate (ThermoFischer Scientific Inc.) was applied to the blot according to the manufacturer&#x2019;s recommendation. The chemiluminescent signals were captured using a CCD camera-based imager. Image analysis software was used to read the band intensity of the target proteins against the control sample after normalization by &#x3b2;-actin (<xref ref-type="bibr" rid="B24">El-Sherbeeny et al., 2020</xref>) on the Chemi Doc MP imager. In addition, ELISA kits were used to determine the level of ATF4 and GRP78.</p>
</sec>
</sec>
<sec id="s2-7">
<title>2.7 Histopathological analysis</title>
<p>Hepatic injury can be detected by hematoxylin and eosin (H&#x26;E) staining of liver tissues (<xref ref-type="bibr" rid="B68">Mousa et al., 2022</xref>; <xref ref-type="bibr" rid="B9">Bilasy et al., 2015</xref>).</p>
<p>The formalin-fixed liver specimens were inserted in liquified paraffin wax and cut into 5-&#x3bc;m thick sections utilizing a Leica microtome (Leica RM 2155, England). Xylene was applied to paraffinized sections to dewax them. The treated sections were then gradually hydrated and subjected to hematoxylin and eosin (H&#x26;E) staining. The sections were blindly screened, examined for histopathological alterations, and scored by an experienced pathologist. Images were captured by a LEICA light microscopy (LEICA ICC50 W, England). Scoring was done according to congestion, inflammatory cell infiltration, and liver cell necrosis. Each variable was scored for each sample slide, and we used a common scoring system where [0] &#x3d; no alteration, [1] &#x3d; mild changes, [2] &#x3d; moderate changes, and [3] &#x3d; severe changes (<xref ref-type="bibr" rid="B41">Kalantar et al., 2019b</xref>; <xref ref-type="bibr" rid="B66">Moodi et al., 2020</xref>).</p>
</sec>
<sec id="s2-8">
<title>2.8 Immunohistochemical analysis</title>
<p>Paraffin sections from different groups of liver tissues from rats were stained by immunohistochemistry (IHC) according to the manufacturing protocol using Anti-caspase 3 antibody (ab4051), at dilution 1:1,000, Anti-Bax antibody (ab32503), at dilution 1:250 and Anti-Bcl-2 antibody (ab182858), at dilution 1:500, (abcam, Cambridge, United Kingdom). The tissue sections from all experimental groups were dewaxed and hydrated (<xref ref-type="bibr" rid="B7">Alomar et al., 2021</xref>). Staining was then performed using the DAB chromogenic agent (Expose mouse and rabbit specific HRP/DAB detection kit, Abcam; Ready-to-use; Cat. &#x23;: ab80436). Counterstaining by hematoxylin was done as a final step (<xref ref-type="bibr" rid="B25">Elsherbiny et al., 2019</xref>). All photos of the tissue sections stained by IHC were captured using a Swift microscope associated with a Swift digital camera. For quantitative analysis, we selected five representative areas from each group. If a tissue section had areas with both low abundance and high abundance of stained cells, both areas were selected as representative areas and included in the analysis. Individual cells were identified by strong brown stain and manually counted. The cell counting was repeated three times for each area. All images were analyzed in a blinded fashion.</p>
</sec>
<sec id="s2-9">
<title>2.9 Data analysis</title>
<p>We used the GraphPad Prism, version 9.1.0 (221) (CA, United States) in statistical analysis. Data of the study were displayed as mean &#xb1; standard error of the mean (SEM). For determining the inter-group variations, we applied the one-way ANOVA test followed by Tukey&#x2019;s <italic>post hoc</italic> test for multiple comparisons. Kruskal&#x2013;Wallis and Dunn&#x2019;s tests were used for analysis and pair-wise comparison of histopathology scoring. A significant difference was assumed if <italic>p</italic>-values were &#x3c;0.05.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>3 Results</title>
<sec id="s3-1">
<title>3.1 Nitazoxanide improved liver function in rats with MTX-hepatotoxicity</title>
<p>As depicted in <xref ref-type="fig" rid="F2">Figure 2</xref>, an impaired liver function was observed in the MTX group compared to CTRL, as indicated by significantly elevated serum liver enzymes. NTZ reduced the elevation in both ALT and AST in a dose-dependent way (<xref ref-type="fig" rid="F2">Figures 2A, B</xref>), whereas a significant reduction in ALP (<xref ref-type="fig" rid="F2">Figure 2C</xref>) was observed with the higher dose (NTZ-200) when compared with the MTX group. Noteworthy, NTZ-200-induced reductions of liver enzymes reached closer levels to those observed with either NAC or 4-PBA.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Effect of 10 days administration of nitazoxanide (NTZ-100 and NTZ-200), N-acetylcysteine (NAC, 500&#xa0;mg/kg), and 4-Phenylbutyric acid (4-PBA) on liver function tests. Liver function is expressed as serum levels of <bold>(A)</bold> ALT, <bold>(B)</bold> AST, and <bold>(C)</bold> ALP. The data presented here are mean &#xb1; SEM. &#x2a; Vs. CTRL; &#x23; Vs. MTX group; &#xa5; Vs. NTZ-100 group, <italic>p</italic> &#x3c; 0.05.</p>
</caption>
<graphic xlink:href="fphar-15-1491249-g002.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>3.2 Nitazoxanide lessened oxidative stress in rats with MTX-hepatotoxicity</title>
<p>As an indicator for lipid peroxidation, hepatic MDA was determined, and a significant rise in hepatic MDA was found in the MTX group as compared to CTRL. NTZ dose-dependently alleviated MTX-induced increase in hepatic MDA, indicating antioxidant properties. NTZ-200 exhibited a better effect than NTZ-100 and resembles the effect of both NAC and 4-PBA (<xref ref-type="fig" rid="F3">Figure 3A</xref>). Further, on evaluating hepatic antioxidant capacity, it was significantly attenuated in MTX group in comparison with CTRL as demonstrated by the significantly lower hepatic GSH and SOD activity (<xref ref-type="fig" rid="F3">Figures 3B, C</xref>). NTZ at both doses significantly enhanced hepatic GSH levels as well as SOD activity with a more pronounced effect with the higher dose, compared to the MTX group. NTZ-200 was close to NAC and 4-PBA effects concerning hepatic SOD activity (<xref ref-type="fig" rid="F3">Figure 3C</xref>), yet it was less effective than both concerning hepatic GSH (<xref ref-type="fig" rid="F3">Figure 3B</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Effect of 10 days administration of nitazoxanide (NTZ-100 and NTZ-200), N-acetylcysteine (NAC, 500&#xa0;mg/kg), and 4-Phenylbutyric acid (4-PBA) on hepatic oxidative stress. Hepatic oxidative stress is demonstrated through <bold>(A)</bold> increased hepatic MDA, <bold>(B)</bold> reduced hepatic reduced glutathione (GSH), and <bold>(C)</bold> superoxide dismutase activity (SOD, <bold>(C)</bold>. Data are means &#xb1; SEM. &#x2a;&#x2a; Vs. CTRL; &#x23; Vs. MTX group; &#xa5; Vs. NTZ-100 group, <italic>p</italic> &#x3c; 0.05.</p>
</caption>
<graphic xlink:href="fphar-15-1491249-g003.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>3.3 Nitazoxanide reduced inflammation in rats with MTX-hepatotoxicity</title>
<p>A profound hepatic inflammation was observed in the MTX group, as demonstrated by significant augmentation in hepatic TNF-&#x3b1;, IL-1&#x3b2;, and IL-6 versus the CTRL group (<xref ref-type="fig" rid="F4">Figures 4A&#x2013;C</xref>). NTZ significantly ameliorated hepatic inflammation by reducing the levels of the proinflammatory cytokines compared to the MTX group in a dose-dependent manner. NTZ-200 approaches the levels reached by both NAC and 4-PBA (<xref ref-type="fig" rid="F4">Figures 4A&#x2013;C</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Effect of 10 days administration of nitazoxanide (NTZ-100 and NTZ-200), N-acetylcysteine (NAC, at 500&#xa0;mg/kg), and 4-Phenylbutyric acid (4-PBA) on hepatic inflammation. Hepatic inflammation is demonstrated by increased hepatic levels of TNF-&#x3b1;, <bold>(A)</bold>, IL-1&#x3b2;, <bold>(B)</bold> and IL-6, <bold>(C)</bold>. Data presented here are mean &#xb1; SEM. &#x2a; Vs. CTRL; &#x23; Vs. MTX group; &#xa5; Vs. NTZ-100 group, <italic>p</italic> &#x3c; 0.05.</p>
</caption>
<graphic xlink:href="fphar-15-1491249-g004.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>3.4 Nitazoxanide reduced apoptosis in rats with MTX-hepatotoxicity</title>
<p>MTX significantly induced hepatic apoptosis as demonstrated by increased proapoptotic markers, Bax level, and caspase-3 activity (<xref ref-type="fig" rid="F5">Figures 5A, D</xref>) while reduced antiapoptotic Bcl-2 level (<xref ref-type="fig" rid="F5">Figure 5B</xref>) and increased Bax/Bcl-2 ratio (<xref ref-type="fig" rid="F5">Figure 5C</xref>) compared to CTRL group. MTX-induced apoptosis was significantly attenuated with all treatments except for NTZ-100, where, as depicted in <xref ref-type="fig" rid="F5">Figures 5A&#x2013;D</xref>, Bcl-2 level was augmented while Bax was reduced, and consequently, Bax/Bcl-2 ratio was also reduced as well as caspase-3 activity all when compared to MTX group. NTZ effects were dose-dependent, where the higher dose was more efficient and closer to the effect of NAC or 4-PBA.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Effect of 10&#xa0;days administration of nitazoxanide (NTZ-100 and NTZ-200) at 100 and 200&#xa0;mg/kg/day, N-acetylcysteine (NAC, 500&#xa0;mg/kg), and 4-Phenylbutyric acid (4-PBA) on hepatic apoptosis. Hepatic apoptosis is expressed by hepatic levels of Bax <bold>(A)</bold>, Bcl-2 <bold>(B)</bold>, Bax/Bcl-2 ratio <bold>(C)</bold>, and caspase-3 activity <bold>(D)</bold>. Data presented here are means &#xb1; SEM. &#x2a; Vs. CTRL; &#x23; Vs. MTX group; &#xa5; Vs. NTZ-100 group, <italic>p</italic> &#x3c; 0.05.</p>
</caption>
<graphic xlink:href="fphar-15-1491249-g005.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>3.5 Nitazoxanide reduced the mRNA expression of ER stress markers in rats with MTX-hepatotoxicity</title>
<p>To determine whether the hepatoprotective effects of NTZ against MTX-hepatotoxicity are associated with ER stress reduction, mRNA expression and the protein level of ER stress markers were determined in liver homogenates. As depicted in <xref ref-type="fig" rid="F6">Figure 6A</xref>, the MTX group exhibited a significant increase in hepatic IRE1 content, a stress sensor protein, compared to CTRL. Further, MTX increased the expression of PERK (<xref ref-type="fig" rid="F6">Figure 6B</xref>), GRP78 (<xref ref-type="fig" rid="F6">Figure 6C</xref>), ATF4 (<xref ref-type="fig" rid="F6">Figure 6D</xref>), and CHOP-10 (<xref ref-type="fig" rid="F6">Figure 6E</xref>) in the liver compared to CTRL, indicating that ER stress is implicated in MTX-induced hepatotoxicity. Hepato-protectant (NAC) and ER stress inhibitor (4-PBA) significantly downregulated ER stress markers in the liver compared to the MTX group, as depicted in <xref ref-type="fig" rid="F6">Figures 6A&#x2013;E</xref>. NTZ significantly attenuated hepatic ER stress induced by MTX, as demonstrated by the downregulation of ER stress markers compared to the MTX group (<xref ref-type="fig" rid="F6">Figures 6A&#x2013;E</xref>). NTZ effects were dose-related, and the higher dose was efficient enough to replicate the 4-PBA effect on ER stress markers.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Effect of 10&#xa0;days administration of nitazoxanide (NTZ-100 and NTZ-200) at 100 and 200&#xa0;mg/kg, respectively, N-acetylcysteine (NAC) at 500&#xa0;mg/kg and 4-Phenylbutyric acid (4-PBA) on hepatic endoplasmic reticulum (ER) stress. Hepatic ER-stress is expressed by hepatic levels of stress sensor protein, inositol-requiring enzyme 1 IRE1, <bold>(A)</bold>, and hepatic mRNA expression of PERK, <bold>(B)</bold>, GRP78, <bold>(C)</bold>, ATF4, <bold>(D)</bold>, and C/EBP homologous protein CHOP-10, <bold>(E)</bold>. Data are means &#xb1; SEM. &#x2a; Vs. CTRL; &#x23; Vs. MTX group; &#xa5; Vs. NTZ-100 group, <italic>p</italic> &#x3c; 0.05.</p>
</caption>
<graphic xlink:href="fphar-15-1491249-g006.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>3.6 Nitazoxanide reduced protein levels of ER stress markers in rats with MTX-hepatotoxicity</title>
<p>
<xref ref-type="fig" rid="F7">Figure 7A</xref> demonstrates the cropped WB gels for experimental groups. Panels 7B and 7C show the protein levels for CHOP-10 and P-PERK, which were significantly increased in the MTX group versus the CTRL group. Rats who received NTZ-100 or NTZ-200&#xa0;mg/kg showed dose-dependent declines in these 2 markers. In addition, the levels of ATF4 and GRP78 are shown in (<xref ref-type="fig" rid="F7">Figures 7D, E</xref>). The MTX group showed significant elevations in hepatic ATF4 and GRP78 versus the CTRL group. NTZ-100 or NTZ-200&#xa0;mg/kg groups produced dose-dependent suppressions in these 2 markers (<xref ref-type="fig" rid="F7">Figures 7D, E</xref>). Further, NAC and 4-PBA groups suppressed the ER stress markers in a significant manner (<xref ref-type="fig" rid="F7">Figures 7B&#x2013;D</xref>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Effect of nitazoxanide on hepatic markers of endoplasmic reticulum stress. <bold>(A)</bold> Cropped Western blot gels for CHOP-10 and P-ERK proteins in the experimental groups (1) CNTR, (2) MTX, (3) MTX &#x2b; NTZ-100, (4) NTZ-200 groups, MTX &#x2b; NAC and MTX &#x2b; 4-PBA. <bold>(B, C)</bold> Column charts for CHOP-10 and P-PERK levels. <bold>(D, E)</bold> Column charts for ATF4 and GRP78 levels. Data are means &#xb1; SEM. &#x2a; Vs. CTRL; Vs. MTX group; &#xa5; Vs. NTZ-100 group, <italic>p</italic> &#x3c; 0.05.</p>
</caption>
<graphic xlink:href="fphar-15-1491249-g007.tif"/>
</fig>
</sec>
<sec id="s3-7">
<title>3.7 Histopathology findings</title>
<p>
<xref ref-type="fig" rid="F8">Figure 8A</xref> shows the features of MTX-induced hepatopathy detected in the liver sections of MTX rats. Livers appeared in a disarrayed pattern with numerous structural abnormalities that can be observed compared to the CTRL rats. Such alterations were depicted as remarkable portal congestion, periportal inflammatory infiltrate, and moderate hepatocyte necrosis (nuclear pyknosis, karyorrhexis, and karyolysis with cytoplasmic eosinophilia), whereas the CTRL group exhibited normal architecture of liver tissue. Histopathological scoring revealed significant portal congestion, periportal inflammatory infiltrate, and hepatocyte necrosis compared to CTRL (<xref ref-type="fig" rid="F8">Figures 8B&#x2013;D</xref>). NTZ at 100&#xa0;mg/kg failed to alleviate hepatic histopathology scoring significantly (<xref ref-type="fig" rid="F8">Figures 8B&#x2013;D</xref>), which is in alignment with the features displayed in photomicrographs of H&#x26;E-stained liver sections where moderate hepatoportal and sinusoidal congestion, moderate periportal inflammatory infiltrate, and moderate hepatocytes necrosis were found. On the other hand, the higher dose of NTZ (200&#xa0;mg/kg) as well as NAC both depicted preserved architecture with mild sinusoidal congestion (<xref ref-type="fig" rid="F8">Figure 8A</xref>) and significantly alleviated histopathological scoring (<xref ref-type="fig" rid="F8">Figures 8B&#x2013;D</xref>). The 4-PBA group showed mild sinusoidal congestion with focal hepatocyte necrosis as manifested by nuclear pyknosis, karyorrhexis, and karyolysis with cytoplasmic eosinophilia (<xref ref-type="fig" rid="F8">Figure 8A</xref>), yet it significantly attenuated histopathological scoring compared to MTX-group (<xref ref-type="fig" rid="F8">Figures 8B&#x2013;D</xref>).</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Effect of 10&#xa0;days administration of nitazoxanide (NTZ-100 and NTZ-200), N-acetylcysteine (NAC) at 500&#xa0;mg/kg, and 4-Phenylbutyric acid (4-PBA) on hepatic histopathological alterations. <bold>(A)</bold> Photomicrograph (H&#x26;E &#xd7;400) of rat livers from different study groups, CTRL group showing a normal architecture of liver tissue with normal central vein (CV). MTX group showing marked portal congestion (P), marked periportal inflammatory infiltrate (arrowheads), and moderate hepatocyte necrosis (asterisks). NTZ-100 group showing moderate hepatoportal (P) and sinusoidal congestion (S), moderate periportal inflammatory infiltrate (arrowheads), and moderate hepatocyte necrosis (asterisks). NTZ-200 group showing the normal architecture of liver tissue with mild sinusoidal congestion (S) Central vein (CV). NAC group showing preserved hepatic architecture with mild sinusoidal congestion (S). Central vein (CV). 4-PBA group showing preserved architecture with mild sinusoidal congestion (S). Central vein (CV). The right panels represent histopathological scoring expressed as congestion score <bold>(B)</bold>, periportal inflammatory cells infiltrate score <bold>(C)</bold>, and hepatocyte necrosis score <bold>(D)</bold>. Data are means &#xb1; SEM. &#x2a; Vs. CTRL; &#x23; Vs. MTX group; &#xa5; Vs. NTZ-100 group, <italic>p</italic> &#x3c; 0.05.</p>
</caption>
<graphic xlink:href="fphar-15-1491249-g008.tif"/>
</fig>
</sec>
<sec id="s3-8">
<title>3.8 Immunohistochemical findings</title>
<p>The immunohistochemical investigation demonstrated a significant increase in expression of proapoptotic makers, Bax, and caspase-3, in MTX treated group, which was associated with decreased antiapoptotic marker, Bcl-2, expression when compared to the CTRL group (<xref ref-type="fig" rid="F9">Figure 9</xref>). Immunohistochemical analysis also revealed a significant decrease in the hepatic expression of both proapoptotic markers Bax and caspase-3 with significant increase in antiapoptotic Bcl-2 expression in rats treated with NTZ-200, NAC or 4-PBA when compared to MTX group (<xref ref-type="fig" rid="F9">Figure 9</xref>).</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>Effect of 10&#xa0;days administration of nitazoxanide (NTZ-100 and NTZ-200), N-acetylcysteine (NAC) at 500&#xa0;mg/kg, and 4-phenylbutyric acid (4-PBA) on hepatic immunohistochemical alterations. The left panels are for <bold>Caspase 3</bold>: Representative photomicrographs of immunostained liver sections for Caspase 3 (Scale bar 20&#xa0;&#x3bc;m) showing: non-detectable expressed cells in CTRL group (A), and NTZ-200 group (D). Numerous positive expressed hepatic cells in MTX group (B). moderate number of stained cells in NTZ-100 group (C). Few labeled cells at both the NAC group (E) and 4-PBA group (F). IHC counterstaining with Mayer&#x2019;s hematoxylin. (Arrowheads refer to positive expressed cells that reveal a golden brown color), <bold>Bcl-2:</bold> Representative photomicrographs of immunostained liver sections for Bcl-2 (Scale bar 20&#xa0;&#x3bc;m) showing marked cytoplasmic expressions within abundant hepatocytes in CTRL group (A), NTZ-200 group (D) and 4-PBA group (F). Negative expressions of Bcl-2 in MTX group (B). Few numbers of expressed hepatocytes in the NTZ-100 group (C). Moderate number of expressed cells in NAC group (E). IHC counterstaining with Mayer&#x2019;s hematoxylin (Arrowheads refer to positive expressed cells that reveal a golden brown color) and <bold>BAX:</bold> Representative photomicrographs of immunostained liver sections for Bax (Scale bar 20&#xa0;&#x3bc;m) showing: no expression in CTRL group (A), NTZ-200 group (D), and 4-PBA group (F). intense numbers of positive labeled hepatocytes in MTX group(B). Moderate number of positive cells at NTZ-100 group (C). Few immuno-labeled cells containing Bax expression in the NAC group (E). IHC counterstaining with Mayer&#x2019;s hematoxylin. (Arrowheads refer to positive expressed cells that reveal a golden brown color). <bold>The right panels</bold> represent the hepatic area % of immunoexpressing cells for caspase-3, BCl2, and BAX. Data are means &#xb1; SEM. &#x2a; Vs. CTRL; &#x23; Vs. MTX group; &#xa5; Vs. NTZ-100 group, <italic>p</italic> &#x3c; 0.05.</p>
</caption>
<graphic xlink:href="fphar-15-1491249-g009.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>4 Discussion</title>
<p>Liver toxicity is a severe outcome of MTX therapy, limiting its clinical use and contributing to its related morbidity and mortality (<xref ref-type="bibr" rid="B17">Conway and Carey, 2017</xref>; <xref ref-type="bibr" rid="B3">Abbas et al., 2023b</xref>). Therefore, searching for potential adjuvant therapies with hepatoprotective capacities to be used during chemotherapy is widely adopted (<xref ref-type="bibr" rid="B53">Liang et al., 2021</xref>) with the need to understand the mechanisms underlying MTX-induced liver toxicity. In this study, we demonstrated the hepatoprotective effect of NTZ, an antiprotozoal drug, against MTX-induced hepatotoxicity. Challenging rats with MTX evoked hepatotoxicity as manifested by elevated liver function enzymes in serum and disarrayed hepatic histopathologic features, which aligns with previous reports (<xref ref-type="bibr" rid="B43">Karabulut et al., 2020</xref>; <xref ref-type="bibr" rid="B67">Morsy et al., 2022</xref>). Pretreatment with NTZ protects the liver against MTX-induced injury as depicted by lower liver enzyme levels in serum and nearly normal histological features, especially with the higher dose; this is following previous reports on NTZ-ameliorative effects on liver injury in CCl4-induced hepatopathy and in steatohepatitis models (<xref ref-type="bibr" rid="B92">Walczak et al., 2018</xref>; <xref ref-type="bibr" rid="B55">Li et al., 2022</xref>; <xref ref-type="bibr" rid="B71">Odagiri et al., 2021</xref>; <xref ref-type="bibr" rid="B91">Vanessa Legry et al., 2022</xref>). Substantial evidence indicates that MTX-induced toxicities implicate oxidative stress (<xref ref-type="bibr" rid="B14">Cetin et al., 2008</xref>; <xref ref-type="bibr" rid="B3">Abbas et al., 2023b</xref>; <xref ref-type="bibr" rid="B2">Abbas et al., 2023a</xref>) and exhaustion of antioxidant defenses, like downregulation of GSH and the &#x201c;Nrf2/heme oxygenase-1&#x201d; signaling (<xref ref-type="bibr" rid="B11">Bu et al., 2018</xref>). This supports our findings where MTX injection evoked oxidative stress with augmented hepatic lipid peroxidation product while declining hepatic antioxidant capacity as depicted by lower GSH and SOD. NTZ significantly alleviated MTX-induced oxidative stress, which can be attributed to the antioxidant properties of its structural moieties (nitrothiazole and salicylamide) (<xref ref-type="bibr" rid="B32">Hemphill et al., 2006</xref>; <xref ref-type="bibr" rid="B22">Elazar et al., 2009</xref>). Our findings are consistent with the oxidative stress suppressive effect of NTZ that underpins its antiviral effect against the influenza-A virus (<xref ref-type="bibr" rid="B37">Huang et al., 2023</xref>) and the chemoprophylactic action in breast cancer (<xref ref-type="bibr" rid="B72">Pal et al., 2020</xref>). Furthermore, using the &#x201c;STITCH database (<ext-link ext-link-type="uri" xlink:href="http://stitch.embl.de/">http://stitch.embl.de/</ext-link>) (<xref ref-type="bibr" rid="B51">Kuhn et al., 2007</xref>),&#x201d; authors evaluated known/predicted protein interactions with NTZ. Our findings revealed a network of interactions in which NTZ may be connected to various proteins critical for oxidative stress, inflammation, and apoptosis (<xref ref-type="bibr" rid="B44">Khayami et al., 2020</xref>; <xref ref-type="bibr" rid="B97">Zhou et al., 2018</xref>; <xref ref-type="bibr" rid="B30">Guo et al., 2024</xref>; <xref ref-type="bibr" rid="B76">Rajak et al., 2022</xref>) (<xref ref-type="fig" rid="F10">Figure 10</xref>).</p>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>Network of predicted protein-interaction of Nitazoxanide (NTZ) in &#x201c;<italic>Rattus norvegicus</italic>,&#x201d; a visual depiction of the potential protein associates of NTZ identified through the &#x201c;STITCH database (<ext-link ext-link-type="uri" xlink:href="http://stitch.embl.de/">http://stitch.embl.de/</ext-link>) (last accessed 27 July 2024).&#x201d; The thickness of the interconnected lines indicates the strength of evidence for each interaction, &#x201c;protein-protein interactions are depicted in grey, while chemical-protein interactions are indicated in green.&#x201d; This network provides additional support for the proposed functions of NTZ in influencing cellular processes associated with oxidative stress, inflammation, and apoptosis. The upper right chemical structure (nitrothiazole and salicylamide) pertains to the NTZ. Abbreviations: &#x201c;Akr1b1, Aldose reductase; Padi4, Protein-arginine deiminase type-4; Akr1e2, 1,5-anhydro-D-fructose reductase; Akr1b8, aldose reductase-related protein 2; Ifitm7, Protein Ifitm7; Ifitm 1/2/3, Interferon-induced transmembrane protein 1/2/3, the Ifitm 3 may inhibit early replication of influenza A virus; Akr1b10, Aldo-keto reductase family 1, member B10; Akr1a1, Alcohol dehydrogenase [NADP (&#x2b;)].&#x201d;</p>
</caption>
<graphic xlink:href="fphar-15-1491249-g010.tif"/>
</fig>
<p>Oxidative stress, associated with high dose MTX, triggers a systemic inflammatory response where proinflammatory cytokines further contribute to tissue damage (<xref ref-type="bibr" rid="B40">Kalantar et al., 2019a</xref>; <xref ref-type="bibr" rid="B38">Hussain et al., 2016</xref>); this reinforces the results of the current study where elevated TNF-&#x3b1;, IL-1&#x3b2;, and IL-6 were noticed in the liver following MTX challenge. Our findings revealed an inflammatory repressing effect of NTZ. Several studies have proven the anti-inflammatory potential of NTZ as it downregulates proinflammatory cytokines in LPS-induced systemic inflammation (<xref ref-type="bibr" rid="B91">Vanessa Legry et al., 2022</xref>), ovariectomized mice (<xref ref-type="bibr" rid="B52">Li et al., 2021</xref>), and type-2 diabetic patients (<xref ref-type="bibr" rid="B13">Castillo-Salazar et al., 2021</xref>) which supports our findings. Generated ROS during MTX administration provoke DNA damage and induce apoptosis via activating intrinsic apoptotic pathways, as documented in various studies (<xref ref-type="bibr" rid="B47">Koppelmann et al., 2012</xref>; <xref ref-type="bibr" rid="B67">Morsy et al., 2022</xref>). In our experiment, the MTX group showed upregulated caspase 3 and the proapoptotic protein, Bax, while downregulated Bcl-2. Hence, we can conclude that these actions may contribute to MTX-induced hepatotoxicity.</p>
<p>During stressful conditions, such as MTX-induced oxidative damage, unresolved ER stress leads to the accumulation of unfolded proteins promoting apoptosis (<xref ref-type="bibr" rid="B88">Teske et al., 2011</xref>). Activated UPR can restore ER homeostasis via integrated intracellular signaling (<xref ref-type="bibr" rid="B34">Hetz, 2012</xref>). ER stress triggers three branch pathways of the UPR, involving activation of transcription factor 6 (ATF6) (<xref ref-type="bibr" rid="B82">Shen et al., 2005</xref>), IRE1 (<xref ref-type="bibr" rid="B16">Chen and Brandizzi, 2013</xref>), and PERK (<xref ref-type="fig" rid="F1">Figure 1</xref>). During ER stress, GRP78, the primary regulator of UPR, dissociates from the ER compartment, activating the main PERK protein pathway. On the other hand, PERK induces translation initiation factor eIF2&#x3b1; phosphorylation (<xref ref-type="bibr" rid="B31">Han et al., 2013</xref>), which activates (ATF4) and CHOP and eventually culminates in apoptotic cell death. The &#x201c;PERK/CHOP-10&#x201d; pathway serves as a significant mediator for cell survival (<xref ref-type="bibr" rid="B31">Han et al., 2013</xref>). The response to ER stress plays a pivotal role in MTX-induced apoptosis, where MTX primarily triggers ER stress via the &#x201c;PERK/CHOP&#x201d; pathway (<xref ref-type="bibr" rid="B84">Song et al., 2021</xref>). In the present investigation, MTX challenge induced ER stress and UPR mainly through the &#x201c;PERK/CHOP&#x201d; pathway, consistent with previous studies on MTX-induced hepatic injury (<xref ref-type="bibr" rid="B79">Schmidt et al., 2022</xref>), nephrotoxicity (<xref ref-type="bibr" rid="B84">Song et al., 2021</xref>), and cognitive impairment (<xref ref-type="bibr" rid="B60">Lv et al., 2020</xref>).</p>
<p>NTZ has been reported to modulate UPR signaling, promoting antioxidant defenses, suppressing inflammatory cytokines, inhibiting PDI, and ultimately preventing cell injury (<xref ref-type="bibr" rid="B19">Di Santo and Ehrisman, 2014</xref>; <xref ref-type="bibr" rid="B18">Di Santo and Ehrisman, 2013</xref>). The IRE1 induces mRNA splicing and induces &#x201c;TNF-associated factor 2 (TRAF2),&#x201d; prompting inflammation/apoptosis (<xref ref-type="bibr" rid="B77">Rajapaksa et al., 2015</xref>). Contrarily, NTZ induces glutathione S-transferase P1, which can mitigate TRAF2 (<xref ref-type="bibr" rid="B70">M&#xfc;ller et al., 2008</xref>). ATF6 induction activates ER chaperone protein release such as PDI (<xref ref-type="bibr" rid="B27">Fung et al., 2014</xref>), whereas NTZ plays a vital part in the maintenance of protective UPR response via PDI suppression (<xref ref-type="bibr" rid="B19">Di Santo and Ehrisman, 2014</xref>; <xref ref-type="bibr" rid="B18">Di Santo and Ehrisman, 2013</xref>). PERK induces phosphorylation for the eIF2&#x3b1; and promotes ATF4, thereby protecting the cell from oxidation (<xref ref-type="bibr" rid="B86">Sureda et al., 2020</xref>), while NTZ upregulates the ATF4 (<xref ref-type="bibr" rid="B8">Ashiru et al., 2014</xref>), demonstrating antioxidant activity. Furthermore, the activation of persistent UPR signaling and PDI is fundamental in the progression of liver disease (<xref ref-type="bibr" rid="B63">Maiers and Malhi, 2019</xref>; <xref ref-type="bibr" rid="B65">Mohan et al., 2019</xref>). To sum up, ER stress activates cytoprotective UPR that favors cell survival under stressful conditions. However, when these conditions remain unresolved, the UPR switches to proapoptotic and inflammatory pathways with persistent accumulation of misfolded proteins promoting cell death (<xref ref-type="bibr" rid="B15">Chen et al., 2023</xref>). Our findings demonstrated attenuated ER stress upon NTZ administration in MTX-challenged rats, which, at least in part, explains the depicted hepatoprotective effects of NTZ herein; this might be attributed to the observed alleviation of oxidative and inflammatory stressful conditions induced by MTX.</p>
<p>Indeed, NTZ and its active circulating metabolite tizoxanide directly protect from stress-induced apoptosis and necroptosis to alleviate liver damage in acute-on-chronic liver failure rat model (<xref ref-type="bibr" rid="B10">Bobowski-Gerard et al., 2024</xref>). <xref ref-type="bibr" rid="B56">Liu et al. (2024)</xref> demonstrated that nitazoxanide and tizoxanide activates AMPK, inhibits STAT3 and Smad2/3 activation, collagen I expression and secretion leading to inhibition of liver fibrosis induced by carbon tetrachloride-induced and bile duct ligation in mice (<xref ref-type="bibr" rid="B56">Liu et al., 2024</xref>). Further, nitazoxanide was reported to activate AMPK in HepG2 cells, mitigate high fat diet-induced hepatic steatosis in C57BL/6J mice and improve western diet-induced hepatic steatosis in <italic>Apoe</italic>
<sup>&#x2212;/&#x2212;</sup> mice (<xref ref-type="bibr" rid="B55">Li et al., 2022</xref>); the authors recommended repurposing nitazoxanide for hepatic steatosis. These findings by other research groups support our findings which indicated that NTZ suppressed MTX-induced oxidative stress and ER stress and eventually the proapoptotic pathways protecting the liver against MTX toxicity.</p>
<p>In our attempt to scrutinize the hepatoprotective potential of NTZ and the possible implication of ER stress inhibition in our model of MTX-induced hepatotoxicity, we compared NTZ effects to a hepatoprotective NAC with documented ER stress inhibition and with a standard ER stress inhibitor (4-PBA) (<xref ref-type="bibr" rid="B83">Soliman et al., 2019</xref>). Both NAC and 4-PBA ameliorated MTX-induced hepatotoxicity as manifested by lowered serum liver function enzymes attenuated histopathological scores and restored normal histological features. NAC hepatoprotective effects may be attributed to its antioxidant capacity in drug-induced hepatotoxicity (<xref ref-type="bibr" rid="B62">Maheswari et al., 2014</xref>; <xref ref-type="bibr" rid="B29">Grisanti et al., 2018</xref>) and streptozotocin-diabetic rats (<xref ref-type="bibr" rid="B26">Erdogan et al., 2023</xref>). Similarly, 4-PBA strongly attenuated oxidative stress in a high-fat diet or ammonia nitrogen-induced liver injury related to its ER stress-inhibiting activity (<xref ref-type="bibr" rid="B20">Dong et al., 2022</xref>). The findings in the present work are congruent with Luo and colleagues&#x2019; report demonstrating the regulatory action of 4-PBA on ER stress-oxidative stress in diabetic nephropathy (<xref ref-type="bibr" rid="B59">Luo et al., 2010</xref>). NAC was reported to repress ER-stress-mediated apoptosis during liver ischemia/reperfusion injury, which aligns with our results (<xref ref-type="bibr" rid="B85">Sun et al., 2014</xref>). Several reports demonstrated the pronounced anti-inflammatory antioxidant effectiveness of NAC (<xref ref-type="bibr" rid="B90">Uraz et al., 2013</xref>; <xref ref-type="bibr" rid="B87">Ten&#xf3;rio et al., 2021</xref>), which further supports our results. ER stress is known to be implicated in the pathology of many inflammatory disease models, including LPS-induced lung inflammation (<xref ref-type="bibr" rid="B45">Kim et al., 2013</xref>), high-fat diet-induced insulin resistance (<xref ref-type="bibr" rid="B96">Yuzefovych et al., 2013</xref>), or chronic graft-versus-host disease (<xref ref-type="bibr" rid="B69">Mukai et al., 2017</xref>). Suppression of ER stress with 4-PBA attenuated the severity of systemic inflammation in such inflammatory disorders and in our model of MTX-induced hepatic inflammation. NTZ, especially at the higher dose, elicited similar hepatoprotective effects comparable to NAC and 4-PBA, indicating the possible involvement of ER stress modulation in NTZ-elicited hepatoprotective effects.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>5 Conclusion</title>
<p>Collectively, it can be concluded that MTX-induced hepatotoxicity is mediated, at least in part, through ER stress, which was confirmed by the reversal of MTX toxicity upon administration of 4-PBA and NAC. NTZ-elicited hepatoprotective effects are suggested to be mediated via modulation of PERK/CHOP10 signaling along with attenuated proapoptotic oxidative stress and proinflammatory signaling. NTZ replicated findings similar to those of the ER stress inhibitor (4-PBA) used in the study, further supporting our conclusion. NTZ is an FDA-approved drug with high safety and reasonable cost and has shown efficient hepatoprotective potential; hence, it can be recommended as adjuvant therapy alongside MTX to counteract its cytotoxic adverse effects.</p>
<p>This study has limitations, particularly the potential underdiagnosis of long-term MTX effects. Another limitation of this study is the lack of experiments exploring the molecular dynamics of NTZ in the improvement of MTX-mediated liver toxicity in more details in a cell culture model. However, because hepatotoxicity is a result of complex mechanisms, animal studies must be performed in association with such <italic>in vitro</italic> experiments. These factors should be taken into consideration in future studies.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec sec-type="ethics-statement" id="s7">
<title>Ethics statement</title>
<p>The animal study was approved by Zagazig University Animal Care and Use Committee (code number ZU-IACUC/3/F/228/2022). The study was conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec sec-type="author-contributions" id="s8">
<title>Author contributions</title>
<p>NM: Investigation, Methodology, Resources, Writing&#x2013;original draft, Writing&#x2013;review and editing, Conceptualization, Data curation. SE: Investigation, Methodology, Resources, Supervision, Writing&#x2013;original draft, Writing&#x2013;review and editing, Conceptualization. FE-s: Data curation, Conceptualization, Writing&#x2013;original draft, Resources, Methodology, Investigation, Formal Analysis. SZ: Formal Analysis, Investigation, Resources, Software, Validation, Visualization, Writing&#x2013;review and editing. AA: Writing&#x2013;review and editing, Visualization, Formal Analysis, Software, Resources, Data curation. GA: Resources, Writing&#x2013;original draft, Validation, Visualization. MF: Investigation, Resources, Software, Writing&#x2013;original draft, Visualization, Writing&#x2013;review and editing. ShA: Funding acquisition, Formal Analysis, Resources, Software, Writing&#x2013;review and editing, Visualization. SaA: Resources, Visualization, Formal Analysis, Investigation, Software, Writing&#x2013;review and editing. TS: Methodology, Formal analysis, Investigation, Resources, Writing&#x2013;original draft. SE-S: Writing&#x2013;review and editing, Conceptualization, Data curation, Formal Analysis, Investigation, Resources, Software.</p>
</sec>
<sec sec-type="funding-information" id="s9">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP 2024R713), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.</p>
</sec>
<ack>
<p>The authors thank Dr. Nelly Mohamed Said, an Assistant Professor at the Department of Pathology, Faculty of Medicine, Zagazig University, for performing the histopathological examination.</p>
</ack>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec sec-type="correction-note" id="s11">
<title>Correction note</title>
<p>A correction has been made to this article. Details can be found at: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.3389/fphar.2026.1880862">10.3389/fphar.2026.1880862</ext-link>.</p>
</sec>
<sec sec-type="disclaimer" id="s12">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="s13">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2024.1491249/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2024.1491249/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abaza</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>El-Zayadi</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Kabil</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Rizk</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Nitazoxanide in the treatment of patients with intestinal protozoan and helminthic infections: a report on 546 patients in Egypt</article-title>. <source>Curr. Ther. Res.</source> <volume>59</volume>, <fpage>116</fpage>&#x2013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/S0011-393X(98)85006-6</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbas</surname>
<given-names>N. A. T.</given-names>
</name>
<name>
<surname>EL-Sayed</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Abd EL-Fatah</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Sarhan</surname>
<given-names>W. M.</given-names>
</name>
<name>
<surname>Abdelghany</surname>
<given-names>E. M. A.</given-names>
</name>
<name>
<surname>Sarhan</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2023a</year>). <article-title>Mechanistic aspects of ameliorative effects of Eicosapentanoic acid ethyl ester on methotrexate-evoked testiculopathy in rats</article-title>. <source>Naunyn Schmiedeb. Arch. Pharmacol.</source> <volume>397</volume>, <fpage>357</fpage>&#x2013;<lpage>369</lpage>. <pub-id pub-id-type="doi">10.1007/s00210-023-02577-4</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbas</surname>
<given-names>N. A. T.</given-names>
</name>
<name>
<surname>El-Sayed</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Abd EL-Fatah</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Sarhan</surname>
<given-names>W. M.</given-names>
</name>
<name>
<surname>Sarhan</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Abdelghany</surname>
<given-names>E. M. A.</given-names>
</name>
<etal/>
</person-group> (<year>2023b</year>). <article-title>Losartan prevents methotrexate-induced liver and lung injury in rats via targeting PPAR-&#x3b3;/TGF-&#x3b2;1/SMAD3 and Nrf2/redox signaling</article-title>. <source>Zagazig Univ. Med. J.</source> <volume>29</volume>, <fpage>135</fpage>&#x2013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.21608/zumj.2022.173474.2682</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abd El-Fadeal</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Nafie</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>K. El-Kherbetawy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>El-Mistekawy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mohammad</surname>
<given-names>H. M. F.</given-names>
</name>
<name>
<surname>Elbahaie</surname>
<given-names>A. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Antitumor activity of nitazoxanide against colon cancers: molecular docking and experimental studies based on wnt/&#x3b2;-catenin signaling inhibition</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume>, <fpage>5213</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22105213</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ali</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rashid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nafees</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hasan</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Shahid</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Majed</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Protective effect of Chlorogenic acid against methotrexate induced oxidative stress, inflammation and apoptosis in rat liver: an experimental approach</article-title>. <source>Chem. Biol. Interact.</source> <volume>272</volume>, <fpage>80</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbi.2017.05.002</pub-id>
<pub-id pub-id-type="pmid">28479099</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>AL Maruf</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>O&#x2019;Brien</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Naserzadeh</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fathian</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Salimi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pourahmad</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Methotrexate induced mitochondrial injury and cytochrome c release in rat liver hepatocytes</article-title>. <source>Drug Chem. Toxicol.</source> <volume>41</volume>, <fpage>51</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1080/01480545.2017.1289221</pub-id>
<pub-id pub-id-type="pmid">28298149</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alomar</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>B</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Eldosoky</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Atef</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mohamed</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Elhawary</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity</article-title>. <source>Int. Immunopharmacol.</source> <volume>90</volume>, <fpage>107193</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2020.107193</pub-id>
<pub-id pub-id-type="pmid">33246827</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashiru</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Howe</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Butters</surname>
<given-names>T. D.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca(2&#x2b;) stores</article-title>. <source>Virology</source> <volume>462-463</volume>, <fpage>135</fpage>&#x2013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2014.05.015</pub-id>
<pub-id pub-id-type="pmid">24971706</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bilasy</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Essawy</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Mandour</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Zaitone</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis</article-title>. <source>Pharmacol. Rep.</source> <volume>67</volume>, <fpage>102</fpage>&#x2013;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharep.2014.08.009</pub-id>
<pub-id pub-id-type="pmid">25560583</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bobowski-Gerard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Debaecker</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stankovic Valentin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tessier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Elkhatib</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Delataille</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>WED-105 Nitazoxanide directly protects from stress-induced cell death to alleviate liver damage in preclinical models of acute-on-chronic liver failure</article-title>. <source>J. Hepatology</source> <volume>80</volume>, <fpage>S191</fpage>. <pub-id pub-id-type="doi">10.1016/S0168-8278(24)00811-0</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Hepatoprotective effect of rhein against methotrexate-induced liver toxicity</article-title>. <source>Eur. J. Pharmacol.</source> <volume>834</volume>, <fpage>266</fpage>&#x2013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2018.07.031</pub-id>
<pub-id pub-id-type="pmid">30031796</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>&#xc7;a&#x11f;lar</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>&#xd6;zg&#xfc;r</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Matur</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Yenilmez</surname>
<given-names>E. D.</given-names>
</name>
<name>
<surname>Tuli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>G&#xf6;nl&#xfc;&#x15f;en</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Ultrastructural evaluation of the effect of N-acetylcysteine on methotrexate nephrotoxicity in rats</article-title>. <source>Histol. Histopathol.</source> <volume>28</volume>, <fpage>865</fpage>&#x2013;<lpage>874</lpage>. <pub-id pub-id-type="doi">10.14670/hh-28.865</pub-id>
<pub-id pub-id-type="pmid">23307329</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castillo-Salazar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>S&#xe1;nchez-Mu&#xf1;oz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Springall Del Villar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Navarrete-V&#xe1;zquez</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hern&#xe1;ndez-Diazcouder</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mojica-Cardoso</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Nitazoxanide exerts immunomodulatory effects on peripheral blood mononuclear cells from type 2 diabetes patients</article-title>. <source>Biomolecules</source> <volume>11</volume>, <fpage>1817</fpage>. <pub-id pub-id-type="doi">10.3390/biom11121817</pub-id>
<pub-id pub-id-type="pmid">34944461</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cetin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kaynar</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kocyigit</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hacioglu</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Saraymen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ozturk</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Role of grape seed extract on methotrexate induced oxidative stress in rat liver</article-title>. <source>Am. J. Chin. Med.</source> <volume>36</volume>, <fpage>861</fpage>&#x2013;<lpage>872</lpage>. <pub-id pub-id-type="doi">10.1142/s0192415x08006302</pub-id>
<pub-id pub-id-type="pmid">19051353</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Stress regulation of WFS1 and PERK-p-eIF2&#x03B1;-ATF4 signaling pathway in placental tissue cells of intrahepatic cholestasis of pregnancy</article-title>. <source>Placenta</source> <volume>139</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2023.05.018</pub-id>
<pub-id pub-id-type="pmid">37269649</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Endoplasmic reticulum stress: molecular mechanism and therapeutic targets</article-title>. <source>Signal Transduct. Target. Ther.</source> <volume>8</volume>, <fpage>352</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-023-01570-w</pub-id>
<pub-id pub-id-type="pmid">37709773</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Brandizzi</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>IRE1: ER stress sensor and cell fate executor</article-title>. <source>Trends cell Biol.</source> <volume>23</volume>, <fpage>547</fpage>&#x2013;<lpage>555</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcb.2013.06.005</pub-id>
<pub-id pub-id-type="pmid">23880584</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conway</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>J. J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Risk of liver disease in methotrexate treated patients</article-title>. <source>World J. Hepatol.</source> <volume>9</volume>, <fpage>1092</fpage>&#x2013;<lpage>1100</lpage>. <pub-id pub-id-type="doi">10.4254/wjh.v9.i26.1092</pub-id>
<pub-id pub-id-type="pmid">28989565</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DI Santo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ehrisman</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Research perspective: potential role of nitazoxanide in ovarian cancer treatment. Old drug, new purpose?</article-title> <source>Cancers (Basel)</source> <volume>5</volume>, <fpage>1163</fpage>&#x2013;<lpage>1176</lpage>. <pub-id pub-id-type="doi">10.3390/cancers5031163</pub-id>
<pub-id pub-id-type="pmid">24202339</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DI Santo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ehrisman</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>A functional perspective of nitazoxanide as a potential anticancer drug</article-title>. <source>Mutat. Res.</source> <volume>768</volume>, <fpage>16</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.mrfmmm.2014.05.005</pub-id>
<pub-id pub-id-type="pmid">25847384</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Oxidative stress can Be attenuated by 4-PBA caused by high-fat or ammonia nitrogen in cultured spotted seabass: the mechanism is related to endoplasmic reticulum stress</article-title>. <source>Antioxidants</source> <volume>11</volume>, <fpage>1276</fpage>. <pub-id pub-id-type="doi">10.3390/antiox11071276</pub-id>
<pub-id pub-id-type="pmid">35883767</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elaidy</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Hussain</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>EL-Kherbetawy</surname>
<given-names>M. K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Time-dependent therapeutic roles of nitazoxanide on high-fat diet/streptozotocin-induced diabetes in rats: effects on hepatic peroxisome proliferator-activated receptor-gamma receptors</article-title>. <source>Can. J. physiology Pharmacol.</source> <volume>96</volume> (<issue>5</issue>), <fpage>485</fpage>&#x2013;<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1139/cjpp-2017-0533</pub-id>
<pub-id pub-id-type="pmid">29244961</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elazar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mckenna</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gehrig</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Puglisi</surname>
<given-names>J. D.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation</article-title>. <source>Gastroenterology</source> <volume>137</volume>, <fpage>1827</fpage>&#x2013;<lpage>1835</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2009.07.056</pub-id>
<pub-id pub-id-type="pmid">19664635</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elmore</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Apoptosis: a review of programmed cell death</article-title>. <source>Toxicol. Pathol.</source> <volume>35</volume>, <fpage>495</fpage>&#x2013;<lpage>516</lpage>. <pub-id pub-id-type="doi">10.1080/01926230701320337</pub-id>
<pub-id pub-id-type="pmid">17562483</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>EL-Sherbeeny</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Soliman</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Youssef</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Abd EL-Fadeal</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>EL-Abaseri</surname>
<given-names>T. B.</given-names>
</name>
<name>
<surname>Hashish</surname>
<given-names>A. A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The protective effect of biochanin A against rotenone-induced neurotoxicity in mice involves enhancing of PI3K/Akt/mTOR signaling and beclin-1 production</article-title>. <source>Ecotoxicol. Environ. Saf.</source> <volume>205</volume>, <fpage>111344</fpage>. <pub-id pub-id-type="doi">10.1016/j.ecoenv.2020.111344</pub-id>
<pub-id pub-id-type="pmid">32977283</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elsherbiny</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Abdel-Mottaleb</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Elkazaz</surname>
<given-names>A. Y.</given-names>
</name>
<name>
<surname>Atef</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lashine</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Youssef</surname>
<given-names>A. M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Carbamazepine alleviates retinal and optic nerve neural degeneration in diabetic mice via nerve growth factor-induced PI3K/Akt/mTOR activation</article-title>. <source>Front. Neurosci.</source> <volume>13</volume>, <fpage>1089</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2019.01089</pub-id>
<pub-id pub-id-type="pmid">31736682</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erdogan</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Erdogan</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Koc</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yalcin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Turk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yetkin</surname>
<given-names>E. A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Hepatoprotective effects of N-acetylcysteine on liver injury by irisin upregulation and oxidative stress reduction in diabetic rats</article-title>. <source>Egypt. Liver J.</source> <volume>13</volume>, <fpage>33</fpage>. <pub-id pub-id-type="doi">10.1186/s43066-023-00271-x</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fung</surname>
<given-names>T. S.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D. X.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Coronavirus-induced ER stress response and its involvement in regulation of coronavirus&#x2013;host interactions</article-title>. <source>Virus Res.</source> <volume>194</volume>, <fpage>110</fpage>&#x2013;<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2014.09.016</pub-id>
<pub-id pub-id-type="pmid">25304691</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grisanti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cosentini</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tovazzi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lazzari</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Consoli</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma</article-title>. <source>Support. Care Cancer</source> <volume>26</volume>, <fpage>2929</fpage>&#x2013;<lpage>2935</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-018-4129-x</pub-id>
<pub-id pub-id-type="pmid">29546526</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Role of AKR1B10 in inflammatory diseases</article-title>. <source>Scand. J. Immunol.</source> <volume>100</volume>, <fpage>e13390</fpage>. <pub-id pub-id-type="doi">10.1111/sji.13390</pub-id>
<pub-id pub-id-type="pmid">38769661</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Back</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Hur</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.-H.</given-names>
</name>
<name>
<surname>Gildersleeve</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death</article-title>. <source>Nat. cell Biol.</source> <volume>15</volume>, <fpage>481</fpage>&#x2013;<lpage>490</lpage>. <pub-id pub-id-type="doi">10.1038/ncb2738</pub-id>
<pub-id pub-id-type="pmid">23624402</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hemphill</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mueller</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Esposito</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections</article-title>. <source>Expert Opin. Pharmacother.</source> <volume>7</volume>, <fpage>953</fpage>&#x2013;<lpage>964</lpage>. <pub-id pub-id-type="doi">10.1517/14656566.7.7.953</pub-id>
<pub-id pub-id-type="pmid">16634717</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zurgil</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Deutsch</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines</article-title>. <source>Inflamm. Res.</source> <volume>54</volume>, <fpage>273</fpage>&#x2013;<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1007/s00011-005-1355-8</pub-id>
<pub-id pub-id-type="pmid">16134056</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hetz</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>The unfolded protein response: controlling cell fate decisions under ER stress and beyond</article-title>. <source>Nat. Rev. Mol. cell Biol.</source> <volume>13</volume>, <fpage>89</fpage>&#x2013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3270</pub-id>
<pub-id pub-id-type="pmid">22251901</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>I. S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S. Y.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice</article-title>. <source>Int. Immunopharmacol.</source> <volume>13</volume>, <fpage>23</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2012.03.002</pub-id>
<pub-id pub-id-type="pmid">22430099</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hourihan</surname>
<given-names>JOHN M.</given-names>
</name>
<name>
<surname>Moronetti</surname>
<given-names>MAZZEO</given-names>
</name>
<name>
<surname>Lorenza</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez-C&#xe1;rdenas</surname>
<given-names>L. P.</given-names>
</name>
<name>
<surname>Blackwell</surname>
<given-names>T. K.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Cysteine sulfenylation directs IRE-1 to activate the SKN-1/Nrf2 antioxidant response</article-title>. <source>Mol. Cell</source> <volume>63</volume>, <fpage>553</fpage>&#x2013;<lpage>566</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2016.07.019</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>The modulation of metabolomics and antioxidant stress is involved in the effect of nitazoxanide against influenza A virus <italic>in vitro</italic>
</article-title>. <source>Acta Virol.</source> <volume>67</volume>. <pub-id pub-id-type="doi">10.3389/av.2023.11612</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hussain</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Blachier</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tossou</surname>
<given-names>M. C. B.</given-names>
</name>
<name>
<surname>Rahu</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Oxidative stress and inflammation: what polyphenols can do for us?</article-title> <source>Oxidative Med. Cell. Longev.</source> <volume>2016</volume>, <fpage>7432797</fpage>. <pub-id pub-id-type="doi">10.1155/2016/7432797</pub-id>
<pub-id pub-id-type="pmid">27738491</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jahovic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cevik</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sehirli</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Ye&#x11f;en</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Sener</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats</article-title>. <source>J. Pineal Res.</source> <volume>34</volume>, <fpage>282</fpage>&#x2013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1034/j.1600-079X.2003.00043.x</pub-id>
<pub-id pub-id-type="pmid">12662351</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalantar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kalantari</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Goudarzi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khorsandi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bakhit</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kalantar</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019a</year>). <article-title>Crocin ameliorates methotrexate-induced liver injury via inhibition of oxidative stress and inflammation in rats</article-title>. <source>Pharmacol. Rep.</source> <volume>71</volume>, <fpage>746</fpage>&#x2013;<lpage>752</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharep.2019.04.004</pub-id>
<pub-id pub-id-type="pmid">31220735</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalantar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kalantari</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Goudarzi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khorsandi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bakhit</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kalantar</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019b</year>). <article-title>Crocin ameliorates methotrexate-induced liver injury via inhibition of oxidative stress and inflammation in rats</article-title>. <source>Pharmacol. Rep.</source> <volume>71</volume>, <fpage>746</fpage>&#x2013;<lpage>752</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharep.2019.04.004</pub-id>
<pub-id pub-id-type="pmid">31220735</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanehisa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kawashima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Furumichi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>KEGG as a reference resource for gene and protein annotation</article-title>. <source>Nucleic Acids Res.</source> <volume>44</volume>, <fpage>D457</fpage>&#x2013;<lpage>D462</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv1070</pub-id>
<pub-id pub-id-type="pmid">26476454</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karabulut</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ozturk</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kuloglu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Akin</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>Kaymak</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Yakan</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Effects of vitamin B12 on methotrexate hepatotoxicity: evaluation of receptor-interacting protein (RIP) kinase</article-title>. <source>Naunyn Schmiedeb. Arch. Pharmacol.</source> <volume>393</volume>, <fpage>2473</fpage>&#x2013;<lpage>2480</lpage>. <pub-id pub-id-type="doi">10.1007/s00210-020-01992-1</pub-id>
<pub-id pub-id-type="pmid">33052426</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khayami</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hashemi</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Kerachian</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential</article-title>. <source>J. Cell Mol. Med.</source> <volume>24</volume>, <fpage>8890</fpage>&#x2013;<lpage>8902</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.15581</pub-id>
<pub-id pub-id-type="pmid">32633024</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Chae</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y. C.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Inhibition of endoplasmic reticulum stress alleviates lipopolysaccharide-induced lung inflammation through modulation of NF-&#x3ba;B/HIF-1&#x3b1; signaling pathway</article-title>. <source>Sci. Rep.</source> <volume>3</volume>, <fpage>1142</fpage>. <pub-id pub-id-type="doi">10.1038/srep01142</pub-id>
<pub-id pub-id-type="pmid">23359618</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koo</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. G.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Endoplasmic reticulum stress in hepatic stellate cells promotes liver fibrosis via PERK-mediated degradation of HNRNPA1 and up-regulation of SMAD2</article-title>. <source>Gastroenterology</source> <volume>150</volume>, <fpage>181</fpage>&#x2013;<lpage>193.e8</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2015.09.039</pub-id>
<pub-id pub-id-type="pmid">26435271</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koppelmann</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pollak</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mogilner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bejar</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Coran</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Sukhotnik</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Dietary L-arginine supplementation reduces Methotrexate-induced intestinal mucosal injury in rat</article-title>. <source>BMC Gastroenterol.</source> <volume>12</volume>, <fpage>41</fpage>. <pub-id pub-id-type="doi">10.1186/1471-230x-12-41</pub-id>
<pub-id pub-id-type="pmid">22545735</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kozminski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Halik</surname>
<given-names>P. K.</given-names>
</name>
<name>
<surname>Chesori</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gniazdowska</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>, <fpage>3483</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21103483</pub-id>
<pub-id pub-id-type="pmid">32423175</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kranz</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Classen</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pompsch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ocklenburg</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>PDI is an essential redox-sensitive activator of PERK during the unfolded protein response (UPR)</article-title>. <source>Cell Death Dis.</source> <volume>8</volume>, <fpage>e2986</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2017.369</pub-id>
<pub-id pub-id-type="pmid">28796255</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pappin</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Tonks</surname>
<given-names>N. K.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>H<sub>2</sub>S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response</article-title>. <source>Sci. Signal.</source> <volume>4</volume>, <fpage>ra86</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.2002329</pub-id>
<pub-id pub-id-type="pmid">22169477</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuhn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>VON Mering</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Campillos</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Bork</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>STITCH: interaction networks of chemicals and proteins</article-title>. <source>Nucleic acids Res.</source> <volume>36</volume>, <fpage>D684</fpage>&#x2013;<lpage>D688</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkm795</pub-id>
<pub-id pub-id-type="pmid">18084021</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C.-H.</given-names>
</name>
<name>
<surname>L&#xfc;</surname>
<given-names>Z.-R.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.-D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.-Y.</given-names>
</name>
<name>
<surname>Leng</surname>
<given-names>H.-J.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>781640</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.781640</pub-id>
<pub-id pub-id-type="pmid">34955850</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.-Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.-Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.-J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.-R.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>S.-Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Nanoplatform-based natural products co-delivery system to surmount cancer multidrug-resistant</article-title>. <source>J. Control. Release</source> <volume>336</volume>, <fpage>396</fpage>&#x2013;<lpage>409</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2021.06.034</pub-id>
<pub-id pub-id-type="pmid">34175367</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.-P.</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>R.-F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z.-J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Antioxidant N-acetylcysteine inhibits maladaptive myocyte autophagy in pressure overload induced cardiac remodeling in rats</article-title>. <source>Eur. J. Pharmacol.</source> <volume>839</volume>, <fpage>47</fpage>&#x2013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2018.08.034</pub-id>
<pub-id pub-id-type="pmid">30194941</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice</article-title>. <source>Acta Pharm. Sin. B</source> <volume>12</volume>, <fpage>1322</fpage>&#x2013;<lpage>1338</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2021.09.009</pub-id>
<pub-id pub-id-type="pmid">35530137</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>K. X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z. Y.</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Z. J.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>The antiprotozoal drug nitazoxanide improves experimental liver fibrosis in mice</article-title>. <source>Biochem. Pharmacol.</source> <volume>224</volume>, <fpage>116205</fpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2024.116205</pub-id>
<pub-id pub-id-type="pmid">38615918</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Sevoflurane relieves hepatic ischemia-reperfusion injury by inhibiting the expression of Grp78</article-title>. <source>Biosci. Rep.</source> <volume>38</volume>. <pub-id pub-id-type="doi">10.1042/bsr20180549</pub-id>
<pub-id pub-id-type="pmid">30217942</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>New insights into the roles of CHOP-induced apoptosis in ER stress</article-title>. <source>Acta Biochim. Biophys. Sin.</source> <volume>46</volume>, <fpage>629</fpage>&#x2013;<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1093/abbs/gmu048</pub-id>
<pub-id pub-id-type="pmid">25016584</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>Z. F.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y. H.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Effects of 4-phenylbutyric acid on the process and development of diabetic nephropathy induced in rats by streptozotocin: regulation of endoplasmic reticulum stress-oxidative activation</article-title>. <source>Toxicol. Appl. Pharmacol.</source> <volume>246</volume>, <fpage>49</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2010.04.005</pub-id>
<pub-id pub-id-type="pmid">20399799</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L. H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Endogenous hydrogen sulfide alleviates methotrexate-induced cognitive impairment by attenuating endoplasmic reticulum stress-induced apoptosis via CHOP and caspase-12</article-title>. <source>Fundam. Clin. Pharmacol.</source> <volume>34</volume>, <fpage>559</fpage>&#x2013;<lpage>570</lpage>. <pub-id pub-id-type="doi">10.1111/fcp.12543</pub-id>
<pub-id pub-id-type="pmid">32034805</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F. F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W. F.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Repurposing nitazoxanide as a novel anti-atherosclerotic drug based on mitochondrial uncoupling mechanisms</article-title>. <source>Br. J. Pharmacol.</source> <volume>180</volume>, <fpage>62</fpage>&#x2013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1111/bph.15949</pub-id>
<pub-id pub-id-type="pmid">36082580</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maheswari</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Saraswathy</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Santhranii</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Hepatoprotective and antioxidant activity of N-acetyl cysteine in carbamazepine-administered rats</article-title>. <source>Indian J. Pharmacol.</source> <volume>46</volume>, <fpage>211</fpage>&#x2013;<lpage>215</lpage>. <pub-id pub-id-type="doi">10.4103/0253-7613.129321</pub-id>
<pub-id pub-id-type="pmid">24741196</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maiers</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Malhi</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Endoplasmic reticulum stress in metabolic liver diseases and hepatic fibrosis</article-title>. <source>Semin. Liver Dis.</source> <volume>39</volume>, <fpage>235</fpage>&#x2013;<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1055/s-0039-1681032</pub-id>
<pub-id pub-id-type="pmid">30912096</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohamed</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Hosney</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bassiony</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hassanein</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Soliman</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Fahmy</surname>
<given-names>S. R.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Sodium pentobarbital dosages for exsanguination affect biochemical, molecular and histological measurements in rats</article-title>. <source>Sci. Rep.</source> <volume>10</volume>, <fpage>378</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-57252-7</pub-id>
<pub-id pub-id-type="pmid">31942001</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>R</surname>
<given-names>P. R. M.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ayyappan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>G</surname>
<given-names>R. K.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Endoplasmic reticulum stress: a master regulator of metabolic syndrome</article-title>. <source>Eur. J. Pharmacol.</source> <volume>860</volume>, <fpage>172553</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172553</pub-id>
<pub-id pub-id-type="pmid">31325433</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moodi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hosseini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abedini</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Hassanzadeh-Taheri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hassanzadeh-Taheri</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Ethanolic extract of Iris songarica rhizome attenuates methotrexate-induced liver and kidney damages in rats</article-title>. <source>Avicenna J. phytomedicine</source> <volume>10</volume>, <fpage>372</fpage>&#x2013;<lpage>383</lpage>. <pub-id pub-id-type="doi">10.22038/ajp.2019.14084</pub-id>
<pub-id pub-id-type="pmid">32850294</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morsy</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Abdel-Latif</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hafez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kandeel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abdel-Gaber</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Paeonol protects against methotrexate hepatotoxicity by repressing oxidative stress, inflammation, and apoptosis-the role of drug efflux transporters</article-title>. <source>Pharm. (Basel)</source> <volume>15</volume>, <fpage>1296</fpage>. <pub-id pub-id-type="doi">10.3390/ph15101296</pub-id>
<pub-id pub-id-type="pmid">36297408</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mousa</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Hammady</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Gad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zaitone</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>EL-Sherbiny</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sayed</surname>
<given-names>O. M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Formulation and characterization of metformin-loaded ethosomes for topical application to experimentally induced skin cancer in mice</article-title>. <source>Pharm. (Basel)</source> <volume>15</volume>, <fpage>657</fpage>. <pub-id pub-id-type="doi">10.3390/ph15060657</pub-id>
<pub-id pub-id-type="pmid">35745575</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Urano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kudo-Saito</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kawakami</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tsubota</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Novel treatment of chronic graft-versus-host disease in mice using the ER stress reducer 4-phenylbutyric acid</article-title>. <source>Sci. Rep.</source> <volume>7</volume>, <fpage>41939</fpage>. <pub-id pub-id-type="doi">10.1038/srep41939</pub-id>
<pub-id pub-id-type="pmid">28165054</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>M&#xfc;ller</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sidler</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nachbur</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Wastling</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brunner</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hemphill</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Thiazolides inhibit growth and induce glutathione-S-transferase Pi (GSTP1)-dependent cell death in human colon cancer cells</article-title>. <source>Int. J. Cancer</source> <volume>123</volume>, <fpage>1797</fpage>&#x2013;<lpage>1806</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.23755</pub-id>
<pub-id pub-id-type="pmid">18688861</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Odagiri</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Matsubara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sato-Matsubara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fujii</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Enomoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kawada</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Anti-fibrotic treatments for chronic liver diseases: the present and the future</article-title>. <source>Clin. Mol. Hepatol.</source> <volume>27</volume>, <fpage>413</fpage>&#x2013;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.3350/cmh.2020.0187</pub-id>
<pub-id pub-id-type="pmid">33317250</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pal</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Nandave</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kaithwas</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Chemoprophylactic activity of nitazoxanide in experimental model of mammary gland carcinoma in rats</article-title>. <source>3 Biotech.</source> <volume>10</volume>, <fpage>338</fpage>. <pub-id pub-id-type="doi">10.1007/s13205-020-02332-z</pub-id>
<pub-id pub-id-type="pmid">32670738</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pawlak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kutkowska</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Obmi&#x144;ska-Mrukowicz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rapak</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Methotrexate induces high level of apoptosis in canine lymphoma/leukemia cell lines</article-title>. <source>Res. Vet. Sci.</source> <volume>114</volume>, <fpage>518</fpage>&#x2013;<lpage>523</lpage>. <pub-id pub-id-type="doi">10.1016/j.rvsc.2017.09.026</pub-id>
<pub-id pub-id-type="pmid">28992489</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perri</surname>
<given-names>E. R.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Parakh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Atkin</surname>
<given-names>J. D.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>The unfolded protein response and the role of protein Disulfide Isomerase in neurodegeneration</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>3</volume>, <fpage>80</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2015.00080</pub-id>
<pub-id pub-id-type="pmid">26779479</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piacentini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>LA Frazia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Riccio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>J. Z.</given-names>
</name>
<name>
<surname>Topai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nicolotti</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57</article-title>. <source>Sci. Rep.</source> <volume>8</volume>, <fpage>10425</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-28172-9</pub-id>
<pub-id pub-id-type="pmid">29992955</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajak</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Anjum</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Raza</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tewari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Role of AKR1B10 and AKR1B8 in the pathogenesis of non-alcoholic steatohepatitis (NASH) in mouse</article-title>. <source>Biochim. Biophys. Acta Mol. Basis Dis.</source> <volume>1868</volume>, <fpage>166319</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2021.166319</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajapaksa</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nikolos</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bado</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gustafsson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>ER&#x3b2; decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway</article-title>. <source>Oncogene</source> <volume>34</volume>, <fpage>4130</fpage>&#x2013;<lpage>4141</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2014.343</pub-id>
<pub-id pub-id-type="pmid">25347741</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossignol</surname>
<given-names>J. F.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Nitazoxanide: a first-in-class broad-spectrum antiviral agent</article-title>. <source>Antivir. Res.</source> <volume>110</volume>, <fpage>94</fpage>&#x2013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2014.07.014</pub-id>
<pub-id pub-id-type="pmid">25108173</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Messner</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Gaiser</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>H&#xe4;mmerli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Suter-Dick</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Methotrexate-induced liver injury is associated with oxidative stress, impaired mitochondrial respiration, and endoplasmic reticulum stress <italic>in vitro</italic>
</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume>, <fpage>15116</fpage>. <pub-id pub-id-type="doi">10.3390/ijms232315116</pub-id>
<pub-id pub-id-type="pmid">36499436</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shakya</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bhat</surname>
<given-names>H. R.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S. K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Update on nitazoxanide: a multifunctional chemotherapeutic agent</article-title>. <source>Curr. Drug Discov. Technol.</source> <volume>15</volume>, <fpage>201</fpage>&#x2013;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.2174/1570163814666170727130003</pub-id>
<pub-id pub-id-type="pmid">28748751</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shea</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Swinden</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Tanjong Ghogomu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ortiz</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Katchamart</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Rader</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis</article-title>. <source>Cochrane Database Syst. Rev.</source> <volume>2013</volume>, <fpage>Cd000951</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD000951.pub2</pub-id>
<pub-id pub-id-type="pmid">23728635</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Snapp</surname>
<given-names>E. L.</given-names>
</name>
<name>
<surname>Lippincott-Schwartz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Prywes</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Stable binding of ATF6 to BiP in the endoplasmic reticulum stress response</article-title>. <source>Mol. Cell. Biol.</source> <volume>25</volume>, <fpage>921</fpage>&#x2013;<lpage>932</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.25.3.921-932.2005</pub-id>
<pub-id pub-id-type="pmid">15657421</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soliman</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Behairy</surname>
<given-names>S. F.</given-names>
</name>
<name>
<surname>EL-Maraghy</surname>
<given-names>N. N.</given-names>
</name>
<name>
<surname>Elshazly</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>PPAR-&#x3b3; agonist, pioglitazone, reduced oxidative and endoplasmic reticulum stress associated with L-NAME-induced hypertension in rats</article-title>. <source>Life Sci.</source> <volume>239</volume>, <fpage>117047</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2019.117047</pub-id>
<pub-id pub-id-type="pmid">31730865</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Interaction of nobiletin with methotrexate ameliorates 7-OH methotrexate-induced nephrotoxicity through endoplasmic reticulum stress-dependent PERK/CHOP signaling pathway</article-title>. <source>Pharmacol. Res.</source> <volume>165</volume>, <fpage>105371</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2020.105371</pub-id>
<pub-id pub-id-type="pmid">33460792</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pu</surname>
<given-names>L. Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X. H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>J. H.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>N-acetylcysteine attenuates reactive-oxygen-species-mediated endoplasmic reticulum stress during liver ischemia-reperfusion injury</article-title>. <source>World J. Gastroenterol.</source> <volume>20</volume>, <fpage>15289</fpage>&#x2013;<lpage>15298</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v20.i41.15289</pub-id>
<pub-id pub-id-type="pmid">25386077</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sureda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alizadeh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nabavi</surname>
<given-names>S. F.</given-names>
</name>
<name>
<surname>Berindan-Neagoe</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cismaru</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Jeandet</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?</article-title> <source>Eur. J. Pharmacol.</source> <volume>882</volume>, <fpage>173288</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173288</pub-id>
<pub-id pub-id-type="pmid">32561291</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ten&#xf3;rio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Graciliano</surname>
<given-names>N. G.</given-names>
</name>
<name>
<surname>Moura</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>A. C. M.</given-names>
</name>
<name>
<surname>Goulart</surname>
<given-names>M. O. F.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>N-acetylcysteine (NAC): impacts on human health</article-title>. <source>Antioxidants (Basel)</source> <volume>10</volume>, <fpage>967</fpage>. <pub-id pub-id-type="doi">10.3390/antiox10060967</pub-id>
<pub-id pub-id-type="pmid">34208683</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teske</surname>
<given-names>B. F.</given-names>
</name>
<name>
<surname>Wek</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Bunpo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cundiff</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Mcclintick</surname>
<given-names>J. N.</given-names>
</name>
<name>
<surname>Anthony</surname>
<given-names>T. G.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress</article-title>. <source>Mol. Biol. cell</source> <volume>22</volume>, <fpage>4390</fpage>&#x2013;<lpage>4405</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.E11-06-0510</pub-id>
<pub-id pub-id-type="pmid">21917591</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tunali-Akbay</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sehirli</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Ercan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sener</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Resveratrol protects against methotrexate-induced hepatic injury in rats</article-title>. <source>J. Pharm. Pharm. Sci.</source> <volume>13</volume>, <fpage>303</fpage>&#x2013;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.18433/j30k5q</pub-id>
<pub-id pub-id-type="pmid">20816014</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uraz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tahan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Aytekin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tahan</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>N-acetylcysteine expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic acid-induced colitis in rats</article-title>. <source>Scand. J. Clin. Lab. Invest</source> <volume>73</volume>, <fpage>61</fpage>&#x2013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.3109/00365513.2012.734859</pub-id>
<pub-id pub-id-type="pmid">23110331</pub-id>
</citation>
</ref>
<ref id="B91">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Vanessa Legry</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Malysiak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Val&#xe9;rie</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Degallaix</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Staels</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2022</year>). &#x201c;<article-title>Improvement of hepatic and extrahepatic functions and anti-inflammatory effects of nitazoxanide in disease models of LPS-induced systemic inflammation and acute-on-chronic liver failure</article-title>,&#x201d; in <source>The international liver congress, cirrhosis and complications</source> (<publisher-loc>London, UK</publisher-loc>: <publisher-name>European Association for the Study of the Liver EASL</publisher-name>). <pub-id pub-id-type="doi">10.3252/pso.eu.ILC2022.2022</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walczak</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Carole</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Benoit</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Descamps</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nathalie</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Megnien</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model</article-title>. <source>J. Hepatology</source> <volume>68</volume>, <fpage>S352</fpage>&#x2013;<lpage>S353</lpage>. <pub-id pub-id-type="doi">10.1016/S0168-8278(18)30928-0</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pareja</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Sevier</surname>
<given-names>C. S.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Redox signaling via the molecular chaperone BiP protects cells against endoplasmic reticulum-derived oxidative stress</article-title>. <source>eLife</source> <volume>3</volume>, <fpage>e03496</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.03496</pub-id>
<pub-id pub-id-type="pmid">25053742</pub-id>
</citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Yiang</surname>
<given-names>G. T.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Anticancer effects of methotrexate in combination with &#x3b1;-tocopherol and &#x3b1;-tocopherol succinate on triple-negative breast cancer</article-title>. <source>Oncol. Rep.</source> <volume>41</volume>, <fpage>2060</fpage>&#x2013;<lpage>2066</lpage>. <pub-id pub-id-type="doi">10.3892/or.2019.6958</pub-id>
<pub-id pub-id-type="pmid">30628707</pub-id>
</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Reactive oxygen species, not Ca(2&#x2b;), mediates methotrexate-induced autophagy and apoptosis in spermatocyte cell line</article-title>. <source>Basic Clin. Pharmacol. Toxicol.</source> <volume>126</volume>, <fpage>144</fpage>&#x2013;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1111/bcpt.13306</pub-id>
<pub-id pub-id-type="pmid">31420979</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuzefovych</surname>
<given-names>L. V.</given-names>
</name>
<name>
<surname>Musiyenko</surname>
<given-names>S. I.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Rachek</surname>
<given-names>L. I.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Mitochondrial DNA damage and dysfunction, and oxidative stress are associated with endoplasmic reticulum stress, protein degradation and apoptosis in high fat diet-induced insulin resistance mice</article-title>. <source>PLoS One</source> <volume>8</volume>, <fpage>e54059</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0054059</pub-id>
<pub-id pub-id-type="pmid">23342074</pub-id>
</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Chaerkady</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mittereder</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>T. S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Evidence for a direct link between PAD4-mediated citrullination and the oxidative burst in human neutrophils</article-title>. <source>Sci. Rep.</source> <volume>8</volume>, <fpage>15228</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-33385-z</pub-id>
<pub-id pub-id-type="pmid">30323221</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>